☒ | |
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
British Columbia, Canada |
98-1566338 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
1550 Leigh Avenue San Jose, California |
95125 | |
(Address of principal executive offices) |
(Zip Code) |
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer |
☒ | Smaller reporting company | ☒ | |||
Emerging growth company | ☒ |
Page |
||||
1 |
||||
3 |
||||
28 |
||||
52 |
||||
53 |
||||
55 |
||||
56 |
||||
57 |
||||
57 |
||||
59 |
||||
60 |
||||
83 |
||||
84 |
||||
85 |
||||
86 |
||||
87 |
||||
87 |
||||
88 |
||||
88 |
||||
88 |
||||
88 |
||||
88 |
||||
88 |
||||
89 |
||||
89 |
||||
91 |
||||
92 |
||||
F-1 |
• | the performance of the Company’s business and operations; |
• | the Company’s expectations regarding revenues, expenses and anticipated cash needs; |
• | the Company’s ability to complete future strategic alliances and the expected impact thereof; |
• | the Company’s ability to source investment opportunities and complete future acquisitions, including in respect of entities in the United States, the ability to finance such acquisitions, and the expected impact thereof; |
• | the expected future business strategy, competitive strengths, goals, expansion and growth of the Company’s business, including operations and plans, new revenue streams and cultivation and licensing assets; |
• | the implementation and effectiveness of the Company’s distribution platform; |
• | expectations with respect to future production costs; |
• | the expected methods to be used by the Company to distribute cannabis; |
• | the competitive conditions of the industry; |
• | laws and regulations and any amendments thereto applicable to the business and the impact thereof; |
• | the competitive advantages and business strategies of the Company; |
• | the application for additional licenses and the grant of licenses or renewals of existing licenses that have been applied for; |
• | the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis; |
• | the Company’s future product offerings; |
• | the anticipated future gross margins of the Company’s operations; |
• | the Company’s ability to source and operate facilities in the United States; |
• | expansion into additional U.S. and international markets; |
• | expectations of market size and growth in the United States and the states in which the Company operates or contemplates future operations; |
• | expectations for regulatory and/or competitive factors related to the cannabis industry generally; and |
• | general economic trends. |
(1) | Other than these subsidiaries, no other subsidiary of the Company has total assets that exceed 10% of the consolidated assets of the Company or revenue that exceeds 10% of the consolidated revenue of the Company or is otherwise considered a “significant subsidiary” within the meaning of Item 1-02(w) of Regulation S-X. |
1) | Direct to Consumer (in-store retail, pick up and delivery): the Company currently operates eleven omni channel retail locations, three in Northern California, three in Central California, and five in Southern California along with six delivery hubs (including the Coastal Holding Company, LLC acquisition as described in this 10-K). |
2) | Wholesale: the Company sells first-party and selected third-party products into 450 dispensaries across California. Additional wholesale revenue comes from sales of sourced bulk flower and oil produced in house. |
Year ended December 31, 2021 |
||||
Direct to consumer |
$ | 54,238,607 | ||
Wholesale |
119,176,274 | |||
|
|
|||
$ | 173,414,881 | |||
|
|
• | A policy and practice of providing equal employment opportunities to all applicants and employees and administering all personnel actions without regard to race, color, creed, religion, sex, sexual orientation, gender identity, marital status, citizenship status, age, national origin, ancestry, disability, veteran status, or any other legally protected status and to affirmatively seek to advance the principles of equal employment opportunity; |
• | The career advancement of all employees, prioritizing promoting from within whenever possible and investing in its workforce to encourage mobility within the organization; |
• | Providing a work environment that is free of unlawful harassment, discrimination or retaliation based on any protected characteristics; and |
• | Providing and maintaining a safe and healthy workplace through ongoing training programs and communication to ensure employees are informed, knowledgeable and able to ensure the safety of themselves and those around them. |
Industry Involvement |
Specific Disclosure Necessary to Fairly Present all Material Facts, Risks and Uncertainties |
Prospectus Cross-Reference | ||
All Issuers with U.S. Marijuana-Related Activities | Describe the nature of the issuer’s involvement in the U.S. marijuana industry and include the disclosures indicated for at least one of the direct, indirect and ancillary industry involvement types noted in this table. | • “ Description of the Business | ||
Prominently state that marijuana is illegal under U.S. federal law and that enforcement of relevant laws is a significant risk. |
• “ United States Regulatory Environment - Cannabis Industry Regulation • “ Risk Factors - Risks Related to the Industry and the Company’s Business’ - Cannabis continues to be a controlled substance under the CSA • “ Risk Factors—Risks Related to the Industry and the Company’s Business - The approach to the enforcement of Regulated Cannabis laws may be subject to change or may not proceed as previously outlined | |||
Discuss any statements and other available guidance made by federal authorities or prosecutors regarding the risk of enforcement action in any jurisdiction where the issuer conducts U.S. marijuana-related activities. Outline related risks including, among others, the risk that third-party service providers could suspend or withdraw services and the risk that regulatory bodies could impose certain restrictions on the issuer’s ability to operate in the U.S. |
• “ United States Regulatory Environment - Cannabis Industry Regulation • “Risk Factors—Risks Related to the Industry and the Company’s Business - Cannabis continues to be a controlled substance under the CSA” • “Risk Factors - Risks Related to the Company’s Products and Services - Service providers could suspend or withdraw service • “Risk Factors—Risks Related to the Industry and the Company’s Business - The Company’s operations in the U.S. cannabis market may be subject to heightened scrutiny by regulatory authorities” | |||
Given the illegality of marijuana under U.S. federal law, discuss the issuer’s ability to access both public and private capital and indicate what financing options are / are not available in order to support continuing operations. | • “Risk Factors—Risks Related to the Industry and the Company’s Business - The Company may have difficulty accessing public and private capitaI” |
• “Risk Factors - Risks Related to the Industry and the Company’s Business - The Company may be subject to applicable anti-money laundering laws and regulations • “Risk Factors—Risks Related to the Industry and the Company’s Business - The Company may have difficulty accessing the services of banks, which may make it difficult to operate its business • “ United States Regulatory Environment - Cannabis Industry Regulation—Laws Applicable to Financial Services for Regulated Cannabis Industry | ||||
Quantify the issuer’s balance sheet and operating statement exposure to U.S. marijuana related activities. | • “ Exposure to U.S. Marijuana Related Activities’“ | |||
Disclose if legal advice has not been obtained, either in the form of a legal opinion or otherwise, regarding (a) compliance with applicable state regulatory frameworks and (b) potential exposure and implications arising from U.S. federal law. | The Company has received and continues to receive legal input, in verbal and written form (including opinions when required), regarding (a) compliance with applicable state and local regulatory frameworks and (b) potential exposure and implications arising from U.S. federal law in certain respects. | |||
U.S. Marijuana Issuers with direct involvement in cultivation or distribution | Outline the regulations for U.S. states in which the issuer operates and confirm how the issuer complies with applicable licensing requirements and the regulatory framework enacted by the applicable U.S. state. Discuss the issuer’s program for monitoring compliance with U.S. state law on an ongoing basis, outline internal compliance procedures and provide a positive statement indicating that the issuer is in compliance with U.S. state law and the related licensing framework. Promptly disclose any non-compliance, citations or notices of violation which may have an impact on the issuer’s license, business activities or operations. |
• “ United States Regulatory Environment – Cannabis Industry Regulation California” • “Description of the Business - Ongoing Compliance” • “Description of the Business - Ongoing Compliance The Company is in compliance with U.S. state law and the related licensing framework. The Company will promptly disclose any noncompliance, citations or notices of violation which may have an impact on their licenses, business activities or operations. |
• | limit access to dispensary premises to medical cannabis patients at least 18 years and older, and adults 21 and over; |
• | maintain a fully operational security alarm system; |
• | contract for professionally-certified security guard services; |
• | maintain a video surveillance system that records continuously 24 hours a day; |
• | ensure that the facility’s outdoor premises have sufficient lighting; |
• | not dispense from its premises outside of permissible hours of operation; |
• | limit the amount of cannabis goods dispensed to individual customers to prevent diversion; |
• | store cannabis and cannabis product only in limited-access areas per the premises diagram submitted to the State of California during the licensing process; |
• | store all cannabis and cannabis products in a secured, locked room or a vault with limited-access areas; |
• | report to local law enforcement within 24 hours after being notified or becoming aware of the theft, diversion, or loss of cannabis; and |
• | ensure the safe transport of cannabis and cannabis products between licensed facilities, maintain a delivery manifest in any vehicle transporting cannabis and cannabis products. Only vehicles that meet DCC distribution requirements are to be used to transport cannabis and cannabis products. |
• | All deliveries of cannabis goods must be performed by a delivery employee (at least 21 years of age) who is directly employed by a licensed retailer. |
• | All deliveries of cannabis goods must be made in person to a physical address that is not on public land. |
• | Prior to providing cannabis goods to a delivery customer, a delivery employee must confirm the identity and age of the delivery customer (as is required if such customer was purchasing the product in the physical dispensary) and ensure that all cannabis goods sold comply with the regulatory requirements. |
• | A licensed cannabis entity is permitted to contract with a service that provides a technology platform to facilitate the sale and delivery of cannabis goods, in accordance with all of the following: (1) the licensed cannabis entity does not allow for delivery of cannabis goods by the technology platform service provider; (2) the licensed entity does not share in the profits of the sale of cannabis goods with the technology platform service provider, or otherwise provide for a percentage or portion of the cannabis goods sales to the technology platform service provider; (3) the licensed cannabis entity does not advertise or market cannabis goods in conjunction with the technology platform service provider, outside of the technology platform, and ensures that the technology platform service provider does not use the licensed cannabis entity’s license number or legal business name on any advertisement or marketing that primarily promotes the services of the technology platform; and (4) provides various disclosures to customers about the source of the delivered cannabis goods. |
License |
Entity w/DBA and License Number |
Address |
Expiration / Renewal Date |
Description | ||||
State of California Retail license issued by BCC. | Caliva CARECE1, LLC dba Kase’s Journey, Inc. License Number: C10- 0000175-LIC |
4030 Farm Supply Road, Ceres, CA 95307 | 06/11/2022 | A retail license covers sales of cannabis goods to customers at its storefront premises or by delivery. A retailer may only purchase cannabis goods that have passed state testing requirements from a licensed distributor. A retailer license may not engage in any packaging or labeling activities. | ||||
State of California Non- Storefront Retail license issued by BCC. |
Martian Delivery, LLC dba Martian Delivery License Number: C9-0000133-LIC |
8880 Elder Creek Road, Sacramento, CA 95828 | 06/25/2022 | A non-storefront retail license covers sales of cannabis goods to customers exclusively through delivery. A retailer non-storefront must have a licensed premise to store the cannabis goods for delivery. The premises of a non-storefront retailer shall not be open to the public. A non-storefront retailer may only purchase cannabis goods that have passed state testing requirements from a licensed distributor. A non-storefront retailer license may not engage in any packaging or labeling activities. | ||||
State of California Medium Indoor Cultivation License issued by California Department of Food and Agriculture (“ CDFA CCL |
NC3 Systems dba Caliva License Number: CCL18-0000047 |
1695 S 7th St San Jose, CA 95112 | 5/24/2022 | A medium cultivation license covers between 10,001 and 22,000 square feet of total canopy. Authorized activities include the planting, growing, harvesting, drying, curing, grading, or trimming of cannabis. Cultivators must use a licensed distributor to transfer product between licensees. |
License |
Entity w/DBA and License Number |
Address |
Expiration / Renewal Date |
Description | ||||
State of California Small Indoor Cultivation License issued by CDFA- CCL | NC3 Systems dba Caliva License Number: CCL18-0000036 |
1695 S 7th St San Jose, CA 95112 | 5/24/2022 | A small cultivation license covers between 5,001 and 10,000 square feet of total canopy. Authorized activities include the planting, growing, harvesting, drying, curing, grading, or trimming of cannabis. Cultivators must use a licensed distributor to transfer product between licensees. | ||||
State of California Small Indoor Cultivation License issued by CDFA- CCL | NC3 Systems dba Caliva License Number: CCL18-0000037 |
1695 S 7th St San Jose, CA 95112 | 5/24/2022 | A small cultivation license covers between 5,001 and 10,000 square feet of total canopy. Authorized activities include the planting, growing, harvesting, drying, curing, grading, or trimming of cannabis. Cultivators must use a licensed distributor to transfer product between licensees. | ||||
State of California Processor License issued by CDFA-CCL |
NC3 Systems dba Caliva License Number: CCL19-0000316 |
1695 S 7th St San Jose, CA 95112 | 5/13/2022 | A processor license covers a cultivation site that conducts only trimming, drying, curing, grading, packaging, or labeling of cannabis and nonmanufactured cannabis products. Cultivators must use a licensed distributor to transfer product between licensees. | ||||
State of California - Nursery License issued by CDFA-CCL |
NC3 Systems dba Caliva License Number: CCL18-0000038 |
1695 S 7th St San Jose, CA 95112 | 5/24/2022 | A nursery license covers a cultivation site that conducts only cultivation of clones, immature plants, seeds, and other agricultural products used specifically for the propagation of cultivation of cannabis. Cultivators must use a licensed distributor to transfer product between licensees. | ||||
State of California Type 6 Manufacturing License issued by California Department of Public Health (“ CDPH MCSB |
NC3 Systems dba Caliva License Number: CDPH-10002244 |
1695 S 7th St San Jose, CA 95112 | 4/2/2022 | A Type 6 manufacturing licensee is authorized to engage in extractions using mechanical methods or nonvolatile solvents (i.e. CO2, ethanol, water or food-grade dry ice, cooking oils, or butter). A Type 6 licensee may also: conduct infusion operations and conduct packaging and labeling of cannabis products. | ||||
State of California Type 6 Manufacturing License issued by CDPH—MCSB | NC4 Systems Inc dba Caliva License Number: CDPH-10002455 |
101-111 South Hill Drive Brisbane, CA 94005 |
4/15/2022 | A Type 6 manufacturing licensee is authorized to engage in extractions using mechanical methods or nonvolatile solvents (i.e. CO2, ethanol, water or food-grade dry ice, cooking oils, or butter). A Type 6 licensee may also: conduct infusion operations and conduct packaging and labeling of cannabis products. |
License |
Entity w/DBA and License Number |
Address |
Expiration / Renewal Date |
Description | ||||
State of California Type 11 Distribution License issued by Bureau of Cannabis Control (“ BCC |
NC3 Systems dba Caliva License Number: C11- 0000819-LIC |
1695 S 7th St San Jose, CA 95112 | 7/15/2022 | Distributor licensees are responsible for transporting cannabis goods between licensees, arranging for testing of cannabis goods, conducting quality assurance review of cannabis goods to ensure they comply with all the packaging and labeling requirements, and distributing cannabis goods and accessories to retailers. A licensed distributor may package and label flower-only products and roll pre-rolls. | ||||
State of California Type 11 Distribution License issued by BCC | NC4 Systems Inc dba Caliva License Number: C11- 0000922-LIC |
101-111 South Hill Drive Brisbane, CA 94005 |
7/28/2022 | Distributor licensees are responsible for transporting cannabis goods between licensees, arranging for testing of cannabis goods, conducting quality assurance review of cannabis goods to ensure they comply with all the packaging and labeling requirements, and distributing cannabis goods and accessories to retailers. A licensed distributor may package and label flower-only products and roll pre-rolls. | ||||
State of California Type 11 Distribution License issued by BCC | Caliva CADINH1, Inc dba Caliva North Hollywood License Number: C11- 0000489-LIC |
7127 Vineland Ave North Hollywood, CA 91605 | 6/24/2022 | Distributor licensees are responsible for transporting cannabis goods between licensees, arranging for testing of cannabis goods, conducting quality assurance review of cannabis goods to ensure they comply with all the packaging and labeling requirements, and distributing cannabis goods and accessories to retailers. A licensed distributor may package and label flower-only products and roll pre-rolls. | ||||
State of California NonStorefront Retail License issued by BCC | NC3 Systems dba Caliva License Number: C9- 0000135-LIC |
1695 S 7th St San Jose, CA 95112 | 6/25/2022 | A non-storefront retail license covers sales of cannabis goods to customers exclusively through delivery. A retailer non-storefront must have a licensed premise to store the cannabis goods for delivery. The premises of a non-storefront retailer shall not be open to the public. A non-storefront retailer may only purchase cannabis goods that have passed state testing requirements from a licensed distributor. A non-storefront retailer license may not engage in any packaging or labeling activities. |
License |
Entity w/DBA and License Number |
Address |
Expiration / Renewal Date |
Description | ||||
State of California Retail License issued by BCC | NC3 Systems dba Caliva License Number: C10- 0000441-LIC |
1695 S 7th St San Jose, CA 95112 | 7/15/2022 | A retail license covers sales of cannabis goods to customers at its storefront premises or by delivery. A retailer may only purchase cannabis goods that have passed state testing requirements from a licensed distributor. A retailer license may not engage in any packaging or labeling activities. | ||||
State of California Retail License issued by BCC | NC3 Systems dba Deli by Caliva License Number: C10- 0000627-LIC |
9535 Artesia Blvd Bellflower, CA 90706 | 10/7/2022 | A retail license covers sales of cannabis goods to customers at its storefront premises or by delivery. A retailer may only purchase cannabis goods that have passed state testing requirements from a licensed distributor. A retailer license may not engage in any packaging or labeling activities. | ||||
State of California Non- Storefront Retail License issued by BCC |
NC4 Systems Inc dba Caliva License Number: C9- 0000235-LIC |
101-111 South Hill Drive Brisbane, CA 94005 |
7/28/2022 | A non-storefront retail license covers sales of cannabis goods to customers exclusively through delivery. A retailer non-storefront must have a licensed premise to store the cannabis goods for delivery. The premises of a non-storefront retailer shall not be open to the public. A non-storefront retailer may only purchase cannabis goods that have passed state testing requirements from a licensed distributor. A non-storefront retailer license may not engage in any packaging or labeling activities. | ||||
State of California Retail License issued by BCC | Nc6 Systems dba Deli by Caliva Hanford License Number: C10- 0000840-LIC |
104 N Douty St Hanford, CA 93230 | 7/12/2022 | A retail license covers sales of cannabis goods to customers at its storefront premises or by delivery. A retailer may only purchase cannabis goods that have passed state testing requirements from a licensed distributor. A retailer license may not engage in any packaging or labeling activities. | ||||
State of California Non- Storefront Retail License issued by BCC |
Caliva CADECC1, LLC dba Caliva Culver City License Number: C9- 0000034-LIC |
5855 Green Valley Circle Culver City, CA 90230 | 5/22/2022 | A non-storefront retail license covers sales of c cannabis goods to customers exclusively through delivery. A retailer non-storefront must have a licensed premise to store the cannabis goods for delivery. The premises of a non-storefront retailer shall not be open to the public. A non-storefront retailer may only purchase cannabis goods that have passed state testing requirements |
License |
Entity w/DBA and License Number |
Address |
Expiration / Renewal Date |
Description | ||||
from a licensed distributor. A nonstorefront retailer license may not engage in any packaging or labeling activities. | ||||||||
State of California - Microbusiness License issued by BCC | Caliva CAMISJ2, Inc. dba Deli by Caliva San Jose License Number: C12- 0000216-LIC |
92 Pullman Way San Jose, CA 95111 | 7/23/2022 | A microbusiness license allows a licensee to engage in the cultivation of cannabis on an area less than 10,000 square feet and to act as a licensed distributor, type 6 manufacturer, and retailer, as specified in an application. In order to hold a microbusiness license, a licensee must engage in at least three (3) of the four (4) listed commercial cannabis activities. At this facility Caliva engages in retail, distribution and manufacturing. | ||||
State of California Non- Storefront Retail License issued by BCC |
Nc5 Systems, Inc. dba Caliva License Number: C9- 0000405-LIC |
1664 Industrial Blvd. Chula Vista, CA 91911 |
4/01/2022 | A non-storefront retail license covers sales of c cannabis goods to customers exclusively through delivery. A retailer non-storefront must have a licensed premise to store the cannabis goods for delivery. The premises of a non-storefront retailer shall not be open to the public. A non-storefront retailer may only purchase cannabis goods that have passed state testing requirements from a licensed distributor. A nonstorefront retailer license may not engage in any packaging or labeling activities. | ||||
State of California Retail License issued by BCC | Calma WeHo, LLC DBA Calma WeHo, LLC License: C10-0000338-LIC |
1155 N La Brea, West Hollywood, CA 90038 | 06/27/2022 | A retail license covers sales of cannabis goods to customers at its storefront premises or by delivery. A retailer may only purchase cannabis goods that have passed state testing requirements from a licensed distributor. A retailer license may not engage in any packaging or labeling activities. |
License |
Entity w/ DBA and License Number |
Address |
Expiration / Renewal Date |
Description | ||||
State of California Type- N Manufacturing | Sturdivant Ventures, LLC dba Landseye |
975 Corporate Center Parkway, | 5/16/2022 | A Type N manufacturing licensee is authorized to produce infused manufactured cannabis products |
License |
Entity w/ DBA and License Number |
Address |
Expiration / Renewal Date |
Description | ||||
License issued by CDPH-MCSB | License Number: CDPH-10003210 |
Suite 120, Santa Rosa, CA 95407 | 5/16/2022 | (e.g., infused pre-rolls, edibles, topicals, other non-inhalable ingestible products). A Type N licensee may also conduct packaging and labeling of manufactured and non-manufactured cannabis products. | ||||
State of California Type- 11 Distribution License issued by BCC | Sturdivant Ventures, LLC dba Landseye License Number: C11- 0000753-LIC |
975 Corporate Center Parkway, Suite 120, Santa Rosa, CA 95407 | 7/9/2022 | Distributor licensees are responsible for transporting cannabis goods between licensees, arranging for testing of cannabis goods, conducting quality assurance review of cannabis goods to ensure they comply with all the packaging and labeling requirements, and distributing cannabis goods and accessories to retailers. A licensed distributor may package and label flower-only products and roll pre-rolls. |
License |
Entity |
Address Attached to License |
Expiration / Renewal Date |
Description | ||||
State of California Type- N Manufacturing License issued by CDPH—MCSB | Fluid South, Inc. dba SOL Distro License Number: CDPH-10003729 |
3560 Cadillac Ave., Costa Mesa, CA | 7/19/2022 | A Type N manufacturing licensee is authorized to produce infused manufactured cannabis products (e.g., infused pre-rolls, edibles, topicals, other non-inhalable ingestible products). A Type N licensee may also conduct packaging and labeling of manufactured and non-manufactured cannabis products. | ||||
State of California Type- 11 Distribution License issued by BCC | Fluid South, Inc. dba SOL Distro License Number: C11- 0000826-LIC |
3560 Cadillac Ave., Costa Mesa, CA | 7/16/2022 | Distributor licensees are responsible for transporting cannabis goods between licensees, arranging for testing of cannabis goods, conducting quality assurance review of cannabis goods to ensure they comply with all the packaging and labeling requirements, and distributing cannabis goods and accessories to retailers. A licensed distributor may package and label flower-only products and roll pre-rolls. |
License |
Entity |
Address Attached to License |
Expiration / Renewal Date |
Description | ||||
State of California Type- 6 Manufacturing License issued by CDPH—MCSB | SISU dba Sisu Extracts License Number: CDPH-10001876 |
4651 West End Road Arcata, CA | 1/12/2022 | A Type 6 manufacturing licensee is authorized to engage in extractions using mechanical methods or nonvolatile solvents (i.e., CO2, ethanol, water or food-grade dry ice, cooking oils, or butter). A Type 6 licensee may also: conduct infusion operations and conduct packaging and labeling of cannabis products. | ||||
State of California Type- 6 Manufacturing License issued by CDPH—MCSB | SISU dba Sisu Extracts License Number: CDPH-10003338 |
112 W. Third Street, Suites D, E, & F Eureka, CA | 5/31/2022 | A Type 6 manufacturing licensee is authorized to engage in extractions using mechanical methods or nonvolatile solvents (i.e. CO2, ethanol, water or food-grade dry ice, cooking oils, or butter). A Type 6 licensee may also: conduct infusion operations and conduct packaging and labeling of cannabis products. | ||||
State of California Type- 11 Distribution License issued by BCC | SISU dba Sisu Extracts License Number: C11- 0000379-LIC |
112 W. Third Street, Suites C Eureka, CA | 6/13/2022 | Distributor licensees are responsible for transporting cannabis goods between licensees, arranging for testing of cannabis goods, conducting quality assurance review of cannabis goods to ensure they comply with all the packaging and labeling requirements, and distributing cannabis goods and accessories to retailers. A licensed distributor may package and label flower-only products and roll pre-rolls. | ||||
State of California Processor License issued by CDFA—CCL | SISU dba Sisu Extracts License Number: CCL20-0001586 |
112 W. Third Street, Suites B Eureka, CA | 8/10/2022 | A processor license covers a cultivation site that conducts only trimming, drying, curing, grading, packaging, or labeling of cannabis and nonmanufactured cannabis products. Cultivators must use a licensed distributor to transfer product between licensees. | ||||
State of California Processor License issued by CDFA—CCL | SISU dba Sisu Extracts License Number: CCL20-0002140 |
228 3rd St. Eureka, CA | 12/17/2022 | A processor license covers a cultivation site that conducts only trimming, drying, curing, grading, packaging, or labeling of cannabis and nonmanufactured cannabis products. Cultivators must use a licensed distributor to transfer product between licensees. |
• | Cannabis continues to be a controlled substance under the CSA. |
• | The approach to the enforcement of Regulated Cannabis laws may be subject to change or may not proceed as previously outlined. |
• | The Company may be subject to applicable anti-money laundering laws and regulations. |
• | The Company may have difficulty accessing the services of banks, which may make it difficult to operate its business. |
• | The Company may have difficulty accessing public and private capital. |
• | The Company may be subject to the risks associated with governmental approvals, permits and compliance with applicable laws. |
• | There may be a restriction on deduction of certain expenses. |
• | Certain jurisdictions currently prohibit public company and/or non-U.S. company ownership of cannabis businesses. |
• | Political uncertainty may have an adverse impact on the Company’s operating performance and results of operations. |
• | Significant failure or deterioration of the Company’s quality control systems may adversely impact the Company. |
• | The Company may be subject to product liability claims. |
• | The Company is subject to risks inherent in an agricultural business. |
• | Ongoing controversy surrounding vaporizers and vaporizer products may materially and adversely affect the market for vaporizer products and expose the Company to litigation and additional regulation. |
• | The Company faces competition from the illegal cannabis market. |
• | The Company may be subject to environmental regulations and risks. |
• | The Company is reliant on its management team. |
• | Potential future sales of shares could adversely affect prevailing market prices for the Common Shares. |
• | Limited market for our securities. |
• | If we fail to comply with the rules under Sarbanes-Oxley related to accounting controls and procedures in the future, or, if we discover material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly and raising capital could be more difficult. |
• | The Company may not be able to achieve sustainable revenues and profitable operations. |
• | Risks associated with recent or future acquisitions. |
• | Competition in the cannabis industry is intense and increased competition by larger and better-financed competitors could materially and adversely affect the business, financial condition and results of operations of the Company. |
• | The cannabis industry is difficult to forecast. |
• | The Company may be subject to the risk of litigation. |
• | Company may be subject to risks related to security breaches. |
• | The current outbreak of the novel Coronavirus, or COVID-19, or the future outbreak of any other highly infectious or contagious diseases, could materially and adversely impact or cause disruption to the Company’s operations, performance, financial condition, results of operations and cash flows. |
• | If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about the Company or its business, the Common Share trading price and volume could decline. |
• | The market price of the Common Shares may be highly volatile. |
• | The Company may be required to take write-downs or write-offs, restructuring and impairment or other charges that could have a significant negative effect on the financial condition, results of operations and Common Share price, which could cause investors to lose some or all of their investment. |
• | a complete or partial closure of, or other operational issues at, one or more of the Company’s |
• | the temporary inability of consumers and patients to purchase the Company’s cannabis products due to a number of factors, including but limited to illness, dispensary closures or limitations on operations (including but not limited to shortened operating hours, social distancing requirements and mandated “curbside only” pickup), quarantine, financial hardship, and “stay at home” orders, could severely impact the Company’s businesses, financial condition and liquidity; |
• | difficulty accessing equity and debt capital on attractive terms, or at all, and a severe disruption and instability in the global financial markets or deteriorations in credit and financing conditions may affect the Company’s access to capital necessary to fund business operations; |
• | workforce disruptions for the Company, as a result of infections, quarantines, stay at home orders or other factors, could result in a material reduction in the Company’s cannabis cultivation, manufacturing, distribution and/or sales capacity; |
• | restrictions on public events for the regulated cannabis industry limit the opportunity for the Company to market and sell its products and promote its brands; |
• | increased cyber security threats due to the increased volume of employees working remotely and using online video-conferencing and collaborative platforms; and |
• | the potential negative impact on the health of the Company’s personnel, particularly if a significant number of them are impacted, would result in a deterioration in the Company’s ability to ensure business continuity during a disruption. |
Location |
Facilities Type |
Approximate Square Footage |
Lease Expiration Dates | |||
Arcata, California (4651 W. End Rd., Ste# D, 95521) |
Manufacturing | 1,211 | 7/31/2022 | |||
Bellflower, California (9535 Artesia Blvd., 90706) |
Dispensary/Retail Dispensary | 4,000 | 9/30/2027 | |||
Bellflower, California (9571 Artesia Blvd, 90706) |
Parking Spaces | 8 Parking Spaces |
12/31/2021 | |||
Brisbane, California (101 South Hill Dr., 94005) |
Retail Delivery/Administrative/Manufacturing/Distribution | 19,150 | 9/30/2023 | |||
Ceres, California (4030 Farm Supply Drive, Ceres, CA 95307) |
Dispensary/Retail Delivery | 3,400 | 4/1/2024 | |||
Costa Mesa, California (3560 Cadillac Ave., 92626) |
Manufacturing/Administrative/Distribution | 20,000 | 8/31/2022 | |||
Costa Mesa, California (2800 Harbor Blvd., 92626) |
Dispensary/Retail Delivery | 4,800 | 5/31/2032 | |||
Chula Vista, California (1664 Industrial Blvd., 91911) |
Retail Delivery | 9,604 | 6/30/2025 | |||
Culver City, California (5855 Green Valley Circle, Ste# 105, 90230) |
Retail Delivery | 2,567 | 6/30/2023 | |||
Emeryville, California (5855 Beudry Street, 94608) |
Retail Delivery | 5,395 | 9/30/2028 | |||
Eureka, California (112 W. 3rd St., Ste# E & F, 95501) |
Processing/Distribution/Manufacturing/Administrative | 2,400(E); 3,600(F) |
11/9/2022 | |||
Eureka, California (112 W. 3rd St., Ste# C & D, 95501) |
(See above) | 2,000(C); 2,000(D) |
8/31/2022 | |||
Eureka, California (112 W. 3rd St., Ste# B, 95501) |
(See above) | 2,000 | 5/31/2023 | |||
Eureka, California (228 3rd St., 95501) |
Processing | 3000 | 7/31/2022 | |||
Eureka, California (205 I St., 95501) |
Administrative | 3,271 | 12/31/2021 | |||
Eureka, California (1313 Broadway, 95501) |
Parking Lot | Parking Lot | 6/1/2022 | |||
Hanford, California (104 North Douty St., 93230) |
Dispensary (Aug. 2021)/Retail Delivery/Administrative | 7,370 | 9/30/2025 |
Hanford, California (10757 Energy Street, 93230) |
Distribution | 20,000 | 1/31/2028 | |||
Redwood City, California (820 Winslow Street, 94063) |
Dispensary (*application filed/TBD) | 1,500 | 12/31/2031 | |||
Sacramento, California (8880 Elder Creek Road, 95828) |
Retail Delivery | 1,400 | 2/4/2023 | |||
San Jose, California (1695 S. 7th St., 95112) |
Dispensary/Retail Delivery/Processing/Cultivation/Distribution/Manufacturing | 110,000 | 9/30/2027 | |||
San Jose, California (92 Pullman Way, 95111) |
Dispensary/Manufacturing/Distribution | 23,000 | 7/31/2022 | |||
San Jose, California (1550 Leigh Ave., 95125) |
Headquarters | 18,692 | 8/31/2023 | |||
San Jose, California (825 S. 5th St., 95112) |
Storage | 30,000 | 9/30/2027 | |||
San Francisco, California (601 Mission Bay Boulevard) |
Event Space | 800 | 6/30/2022 | |||
Santa Rosa, California (975 Corporate Center Parkway, Ste #120 & 125) |
Manufacturing/ Distribution (non-operational/for sale) |
20,000 | 9/30/2026 | |||
West Hollywood, California (1155 N. La Brea Ave. 90038) |
Dispensary/Retail Delivery | 3,250 | 12/31/2023 |
Plan Category |
Number of Securities to be Issued upon Exercise of Outstanding Options, Warrants and Rights |
Weighted- Average Exercise Price of Outstanding Options, Warrants and Rights |
Number of Securities Remaining Available for Future Issuance under Equity Compensation Plans (excluding securities reflected in Column “(a)”) |
|||||||||
(a) |
(b) |
(c) |
||||||||||
Equity compensation plans approved by security holders(l) |
||||||||||||
Equity Incentive Plan |
9,706,509 | (1) | — | 6,395,989 | (2) | |||||||
Equity compensation plans not approved by security holders |
||||||||||||
Caliva EIP |
738,853 | (3) | $ | 7.34 | — | |||||||
LCV Equity Plan |
16,815 | (3) | $ | 25.98 | — | |||||||
Total |
10,462,177 | 6,395,989 |
(1) | Represents Common Shares that may be issued upon the vesting and settlement of outstanding restricted share units. |
(2) | The maximum number of Common Shares that may be issued under the Equity Incentive Plan is 10.0% of the Common Shares outstanding from time to time, subject to adjustment in accordance with the Equity Incentive Plan. |
(3) | Represents Common Shares that may be issued upon the exercise of outstanding options. |
1) | Direct to Consumer (in-store retail, pick up and delivery): the Company currently operates eleven omni channel retail locations: three in northern California, three in central California, five in southern California and six delivery hubs. Further, on October 4, 2021, the Company announced that it had signed definitive agreements to acquire Coastal Holding Company, LLC (“Coastal |
2) | Wholesale: the Company sells first party and selected third party products into 450 dispensaries across California. Additional wholesale revenue comes from sales of sourced bulk flower and oil produced in house. |
Year ended December 31, 2021 |
Year ended December 31, 2020 |
|||||||
Direct to consumer |
$ | 54,238,607 |
$ | — | ||||
Wholesale |
119,176,274 |
— |
||||||
|
|
|
|
|||||
$ | 173,414,881 |
— |
||||||
|
|
|
|
• | Issued a remote work directive for all non-essential employees; |
• | Instituted a mandatory face mask policy in all The Parent Company locations and for all customer deliveries; |
• | Implemented staggered work schedules, employee breaks and redesigned workstations and processes to minimize employee interaction and ensure appropriate social distancing; |
• | Minimized the number of essential employees moving between The Parent Company locations; |
• | Banned all non-essential contractors, vendors and visitors from our locations to reduce flow of traffic into and out of our facilities, as well as encouraged meetings with third parties to be virtual; |
• | Enhanced sanitation of work areas, both in terms of breadth and depth of cleanings, including industrial cleaning and sanitizing protocols upon detection of a COVID-19 positive test; |
• | Required employees to stay home if not feeling well, informing employees of government and health authority guidelines, and facilitating testing; |
• | Implemented contact tracing system and mandatory 14-day quarantines for all workers potentially exposed to someone testing positive for COVID-19 and any employees returning from out of country visits; |
• | Issued directives to customer-facing teams in retail and delivery with regard to frequent cleaning, social distancing, and customer safety; |
• | Suspended all but critical business travel; |
• | Enhanced communication creating a 24-hour Employee Hotline, a COVID-19 resource, policy and information page on The Parent Company’s intranet, frequent employee communications and training; |
Caliva/OGE |
LCV |
SISU |
Total |
|||||||||||||
Total consideration transferred (i) |
$ | 619,766,731 | $ | 120,651,941 | $ | 92,188,146 | $ |
832,606,818 |
||||||||
|
|
|
|
|
|
|
|
|||||||||
Assets acquired |
||||||||||||||||
Cash, restricted cash and cash equivalents |
11,164,957 | 3,022,262 | 976,906 | 15,164,125 |
||||||||||||
Accounts receivable |
2,006,699 | 1,090,811 | 1,022,532 | 4,120,042 |
||||||||||||
Inventory |
11,910,959 | 6,258,063 | 5,580,258 | 23,749,280 |
||||||||||||
Prepaid expenses |
3,589,808 | 215,938 | 82,701 | 3,888,447 |
||||||||||||
Indemnification assets |
2,199,029 | 2,000,000 | — | 4,199,029 |
||||||||||||
Property and equipment |
7,785,157 | 3,305,145 | 1,163,902 | 12,254,204 |
||||||||||||
Intangible assets |
187,600,000 | 20,740,000 | 46,200,000 | 254,540,000 |
||||||||||||
Right-of-use |
12,115,573 | 4,461,809 | 880,863 | 17,458,245 |
||||||||||||
Right-of-use |
26,176,837 | — | — | 26,176,837 |
||||||||||||
Investment in associate |
— | 6,500,000 | — | 6,500,000 |
||||||||||||
Investment in non-marketable securities |
591,545 | — | — | 591,545 |
||||||||||||
Security deposits and other |
869,238 | 137,051 | 34,175 | 1,040,464 |
||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total assets acquired |
266,009,802 | 47,731,079 | 55,941,337 | 369,682,218 |
||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Liabilities assumed |
||||||||||||||||
Accounts payable and accrued liabilities |
26,130,222 | 14,817,802 | 8,242,144 | 49,190,168 |
||||||||||||
Consideration payable |
2,458,844 | 2,972,782 | — | 5,431,626 |
||||||||||||
Loans payable |
3,060,250 | 298,436 | — | 3,358,686 |
||||||||||||
Line of credit |
— | — | 1,000,000 | 1,000,000 |
||||||||||||
Deferred tax liability |
35,483,327 | 4,199,766 | — | 39,683,093 |
||||||||||||
Lease liabilities |
49,746,261 | 4,461,809 | 1,183,451 | 55,391,521 |
||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total liabilities assumed |
116,878,904 | 26,750,595 | 10,425,595 | 154,055,094 |
||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Goodwill |
$ | 470,635,833 | $ | 99,671,457 | $ | 46,672,404 | $ |
616,979,694 |
||||||||
|
|
|
|
|
|
|
|
Caliva/OGE |
LCV |
SISU |
Total |
|||||||||||||
Upfront consideration |
||||||||||||||||
Cash |
$ | 465,140 | $ | 177,970 | $ | 11,089,535 | $ |
11,732,645 |
||||||||
Liabilities settled in cash as part of the Qualifying Transaction |
12,614,773 | 15,400,000 | 3,560,593 | 31,575,366 |
||||||||||||
Liabilities settled in shares as part of the Qualifying Transaction |
— | — | 4,264,597 | 4,264,597 |
||||||||||||
Common shares |
408,178,567 | 57,529,825 | 63,581,153 | 529,289,545 |
||||||||||||
Common shares to be issued |
1,567,549 | 5,897,750 | 9,692,268 | 17,157,567 |
||||||||||||
Consideration payable |
1,000 | 5,120 | — | 6,120 |
||||||||||||
Contingent consideration (liability) – Trading price consideration |
191,077,970 | 41,641,276 | — | 232,719,246 |
||||||||||||
Contingent consideration (liability) – Other |
— | — | — | — |
||||||||||||
Contingent consideration (equity) |
2,372,231 | — | — | 2,372,231 |
||||||||||||
Replacement options |
3,489,501 | — | — | 3,489,501 |
||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total consideration transferred |
$ |
619,766,731 |
$ |
120,651,941 |
$ |
92,188,146 |
$ |
832,606,818 |
||||||||
|
|
|
|
|
|
|
|
a) | Trading price consideration 20-day volume weighted average trading price (“VWAP”) of the Common Shares reaches $13.00, $17.00 and $21.00 within three years of closing, with one-third issuable upon the achievement of each price threshold, respectively. The pool of Common Shares is to be shared with Caliva option holders who were employees of Caliva at the time of the transaction (“Caliva employee option holders”). In order to receive their stock of the contingent consideration, Caliva employee option holders must be employed by the Company at the time the contingent consideration is paid out. The portion of the pool of common stock that may be paid to Caliva employee option holders is being accounted for as employee stock-based compensation and is being expensed over the estimated vesting period. The portion of the pool of Common Shares that may be paid to former Caliva and OGE stockholders is being accounted for as contingent consideration in the amount of $191,077,970 and is included in the consideration transferred above. |
b) | Earn-out stock |
c) | Other |
d) | 187,380 Common Shares of TPCO have been placed into escrow and will be issued when subsidiaries of Caliva receive their licenses. This is presented as contingent stock to be issued in equity. If the licenses are not obtained, the stock will be issued to Caliva former stockholders, and therefore have been included as part of consideration. |
a) | Trading price consideration 20-day VWAP of the common stock reaches $13.00, $17.00 and $21.00 within three years of closing, with one-third issuable upon the achievement of each price threshold, respectively. The fair value of the contingent consideration on January 15, 2021 was $41,641,276 and is included in consideration transferred above. |
b) | Other |
Years ended |
||||||||
December 31, 2021 |
December 31, 2020 |
|||||||
Sales |
$ | 173,414,881 | — | |||||
Cost of sales |
153,182,191 | — | ||||||
|
|
|
|
|||||
Gross profit |
20,232,690 | |||||||
Impairment loss |
654,317,300 | |||||||
Operating expenses |
184,433,403 | 8,813,918 | ||||||
|
|
|
|
|||||
Loss from operations |
(818,518,013 | ) | (8,813,918 | ) | ||||
Other |
||||||||
Interest income |
1,244,606 | 2,350,312 | ||||||
Interest expense |
(5,183,817 | ) | — | |||||
Gain on debt forgiveness |
3,358,686 | — | ||||||
Loss on disposal of assets |
(2,447,985 | ) | — | |||||
Change in fair value of investments at FVTPL |
(1,250,990 | ) | — | |||||
Change in fair value of contingent consideration |
229,819,070 | — | ||||||
Other income |
3,573,557 | — | ||||||
|
|
|
|
|||||
229,113,127 | 2,350,312 | |||||||
|
|
|
|
|||||
Loss before income taxes |
(589,404,886 | ) | (6,463,606 | ) | ||||
Income tax recovery |
2,372,552 | — | ||||||
|
|
|
|
|||||
Loss and comprehensive loss |
$ | (587,032,334 | ) | $ | (6,463,606 | ) | ||
|
|
|
|
|||||
Loss and comprehensive loss attributable to shareholders of the company |
$ | (587,060,124 | ) | $ | — | |||
Loss and comprehensive loss attributable to redeemable non-controlling interest |
27,790 | (6,463,606 | ) | |||||
|
|
|
|
|||||
Loss and comprehensive loss |
$ | (587,032,334 | ) | $ | (6,463,606 | ) | ||
|
|
|
|
|||||
Loss per share |
||||||||
Basic and Diluted |
$ | (6.18 | ) | $ | (1.90 | ) | ||
Weighted average number of common shares |
95,006,080 | 15,218,750 | ||||||
Basic and Diluted |
Year ended December 31, 2021 |
Year ended December 31, 2020 |
|||||||
Direct to consumer |
$ | 54,238,607 | $ | — |
||||
Wholesale |
119,176,274 | — |
||||||
|
|
|
|
|||||
$ |
173,414,881 |
$ |
— |
|||||
|
|
|
|
Year ended |
||||||||
December 31, 2021 |
December 31, 2020 |
|||||||
General and administrative |
$ |
47,289,538 |
$ | 8,813,918 | ||||
Allowance for doubtful accounts |
4,677,134 |
|||||||
Sales and marketing |
42,572,823 |
— | ||||||
Salaries and benefits |
36,864,880 |
— | ||||||
Stock compensation expense |
20,456,297 |
— | ||||||
Lease expense |
4,956,969 |
— | ||||||
Depreciation |
3,890,425 |
— | ||||||
Amortization of intangible assets |
23,725,337 |
— | ||||||
|
|
|
|
|||||
184,433,403 |
$ |
8,813,918 |
||||||
|
|
|
|
Year ended |
||||||||
December 31, 2021 |
December 31, 2020 |
|||||||
Non-THC business (i) |
5,555,437 |
— | ||||||
Assets held for sale (ii) |
1,995,945 |
— | ||||||
Impairment |
646,765,918 |
— | ||||||
|
|
|
|
|||||
$ |
654,317,300 |
$ | — | |||||
|
|
|
|
Year ended |
||||||||
December 31, 2021 |
December 31, 2020 |
|||||||
Net loss and comprehensive loss |
$ |
(587,032,334 |
) |
$ |
(6,463,606 |
) | ||
Income tax |
(2,372,552 | ) | — | |||||
Depreciation and amortization |
27,615,762 | — |
Year ended |
||||||||
December 31, 2021 |
December 31, 2020 |
|||||||
Interest expense and debt amortization |
5,183,817 | — | ||||||
|
|
|
|
|||||
EBITDA |
(556,605,307 | ) | (6,463,606 | ) | ||||
|
|
|
|
|||||
Adjustments: |
||||||||
Share based compensation expense |
20,456,297 | — | ||||||
Other non-recurring items: |
— | |||||||
Fair value change of contingent consideration |
(229,819,070 | ) | — | |||||
Loss on disposal of assets |
2,447,985 | — | ||||||
Change in fair value of investments at FVTPL |
1,250,990 | — | ||||||
Impairment loss |
654,317,300 | — | ||||||
Provision for notes receivable |
2,660,943 | |||||||
Write-off of prepaid inventory |
1,620,891 | |||||||
Canadian tax on SPAC share redemption |
2,243,441 | — | ||||||
De-SPAC costs |
5,341,154 | — | ||||||
Restructuring costs |
3,878,782 | — | ||||||
Non-cash sales and marketing expense |
30,166,667 | — | ||||||
|
|
|
|
|||||
Adjusted EBITDA |
$ | (62,039,927 |
) |
$ |
(6,463,606 |
) | ||
|
|
|
|
Operating Lease |
Finance Lease |
|||||||
2022 |
$ | 6,774,561 | $ | 4,493,443 | ||||
2023 |
5,662,221 | 4,625,156 | ||||||
2024 |
5,281,010 | 4,763,910 | ||||||
2025 |
5,081,629 | 4,906,828 | ||||||
2026 |
4,647,394 | 5,054,033 | ||||||
Thereafter |
23,921,870 | 64,884,897 | ||||||
|
|
|
|
|||||
Total undiscounted lease liabilities |
51,368,685 | 88,728,267 |
Year ended |
||||||||
December 31, 2021 |
December 31, 2020 |
|||||||
Cash provided by (used in) |
||||||||
Operating activities |
||||||||
Net income (loss) |
$ |
(587,032,334 |
) |
(6,463,606 | ) | |||
Adjustments for items not involving cash |
||||||||
Impairment loss |
654,317,300 | — | ||||||
Loss on disposal of assets |
2,447,985 | — | ||||||
Gain on debt forgiveness |
(3,358,686 | ) | — | |||||
Change in fair value of investments at FVTPL |
1,250,990 | — | ||||||
Interest expense |
5,183,817 | — | ||||||
Provision for bad debt |
2,016,191 | — | ||||||
Provision for note receivable |
2,660,943 | — | ||||||
Non-cash interest income |
(1,149,041 | ) | — | |||||
Depreciation and amortization |
27,615,762 | — | ||||||
Shares issued for long-term strategic contracts |
25,000,000 | — | ||||||
Stock compensation expense, net of withholding taxes |
19,663,385 | — | ||||||
Non-cash operating lease expense |
4,956,969 | |||||||
Non-cash marketing expense |
5,166,666 | — | ||||||
Fair value change of contingent consideration |
(229,819,070 | ) | — | |||||
Deferred income tax recovery |
(5,590,409 | ) | — | |||||
Repayment of operating lease liabilities |
(5,190,663 | ) | — | |||||
Net changes in non-cash working capital items |
(46,513,086 | ) | 8,813,918 | |||||
|
|
|
|
|||||
Total operating |
(128,373,281 | ) | 2,350,312 | |||||
|
|
|
|
|||||
Financing activities |
||||||||
Proceeds from private placement |
51,635,000 | — | ||||||
Redemption of Class A restricted voting shares |
(264,318,686 | ) | — | |||||
Proceeds from exercise of options |
12,972 | — | ||||||
Repayment of consideration payable |
(1,034,417 | ) | — | |||||
Repayment of finance lease liabilities |
(4,385,528 | ) | — | |||||
Repurchase of stock |
(6,542,196 | ) | — | |||||
Repayment of line of credit |
(1,000,000 | ) | — | |||||
|
|
|
|
|||||
Total financing |
(225,632,855 | ) | — | |||||
|
|
|
|
|||||
Investing activities |
||||||||
Net cash paid in business combinations for Qualifying Transaction |
(28,143,886 | ) | — | |||||
Net cash paid in business combinations |
(20,612,867 | ) | ||||||
Advances for note receivable |
(5,650,000 | ) | — | |||||
Advances for investments at FVTPL |
(1,000,0000 | ) | — | |||||
Purchases of property and equipment |
(9,760,359 | ) | — | |||||
Proceeds from notes receivable |
374,984 | — | ||||||
Proceeds from sale of net assets |
11,068,537 | |||||||
|
|
|
|
|||||
Total investing |
(53,723,591 | ) | — | |||||
Net change in cash during the year |
(407,729,727 | ) | 2,350,312 | |||||
Cash, Restricted cash and restricted cash equivalents |
||||||||
Beginning of year |
$ |
582,622,025 |
580,271,713 | |||||
|
|
|
|
|||||
End of year |
$ |
174,892,298 |
582,622,025 | |||||
|
|
|
|
|||||
Cash |
165,310,609 |
— | ||||||
Restricted cash and restricted cash equivalents |
9,581,689 |
582,622,025 | ||||||
|
|
|
|
|||||
Cash, restricted cash and restricted cash equivalents |
$ |
174,892,298 |
$ | 582,622,025 | ||||
|
|
|
|
• |
From the customer’s perspective, the only party they interact with is the Company. The customer does not know the origin of the product and there is no brand recognition associated with the product (i.e., the products do not carry a brand name, and instead the labels only carry information with respect to the contents of the package). |
• |
If the customer returns the product, the Company will decide whether to take the product back and refund the customer, and the Company will have no right to compensation from the supplier. As a result, the Company has back-end inventory risk. |
• |
The Company has discretion in setting prices and in many cases the supplier does not know the amount the Company sold the products for. |
• |
To ensure sufficient financial flexibility to achieve the ongoing business objectives including of future growth opportunities, and pursuit of accretive acquisitions; and |
• |
To maximize shareholder return through enhancing the share value. |
(a) (1) |
Financial Statements |
See the accompanying Index to Consolidated Financial Statement Schedule on page F-1. |
(a) (2) |
Financial Statement Schedules |
See the accompanying Index to Consolidated Financial Statement Schedule on page F-1. |
(a) (3) |
Exhibits |
Incorporated by Reference From |
||||||||||||||||
Exhibit No. |
Title of Document |
Form |
Date Filed |
Exhibit Number |
Filed Herewith |
|||||||||||
2.1* |
10-12G |
9/30/2021 |
2.1 |
|||||||||||||
2.2* |
10-12G |
9/30/2021 |
2.2 |
|||||||||||||
2.3* |
10-12G |
9/30/2021 |
2.3 |
|||||||||||||
2.4* |
10-12G |
9/30/2021 |
2.4 |
|||||||||||||
2.5*† |
10-12G/A |
10/27/2021 |
2.5 |
|||||||||||||
3.1 |
10-12G |
9/30/2021 |
3.1 |
|||||||||||||
3.2 |
10-12G/A |
10/01/2021 |
3.2 |
|||||||||||||
3.3 |
10-12G |
9/30/2021 |
3.3 |
|||||||||||||
4.1 |
10-12G |
9/30/2021 |
4.1 |
|||||||||||||
4.2 |
10-12G |
9/30/2021 |
4.2 |
|||||||||||||
4.3 |
X |
|||||||||||||||
10.1 |
10-12G |
9/30/2021 |
10.1 |
|||||||||||||
10.2 |
10-12G |
9/30/2021 |
10.2 |
10.3+ |
10-12G |
9/30/2021 |
10.3 |
|||||||||||||
10.4+ |
10-12G |
9/30/2021 |
10.4 |
|||||||||||||
10.5+ |
10-12G |
9/30/2021 |
10.5 |
|||||||||||||
10.6+ |
10-12G |
9/30/2021 |
10.6 |
|||||||||||||
10.7+ |
10-12G |
9/30/2021 |
10.7 |
|||||||||||||
10.8 |
10-12G |
9/30/2021 |
10.8 |
|||||||||||||
10.9+ |
10-12G |
9/30/2021 |
10.9 |
|||||||||||||
10.10+ |
10-12G/A |
10/01/2021 |
10.10 |
|||||||||||||
10.11+ |
10-12G/A |
10/01/2021 |
10.11 |
|||||||||||||
10.12 |
10-12G/A |
10/01/2021 |
10.13 |
|||||||||||||
10.13†† |
10-12G/A |
12/09/2021 |
10.14 |
|||||||||||||
10.14†† |
10-12G/A |
12/09/2021 |
10.15 |
|||||||||||||
10.15+ |
8-K |
2/7/2022 |
10.1 |
|||||||||||||
21.1 |
— |
— |
— |
X |
||||||||||||
23.1 |
— |
— |
— |
X |
||||||||||||
24.1 |
— |
— |
— |
X |
||||||||||||
31.1 |
— |
— |
— |
X |
||||||||||||
31.2 |
— |
— |
— |
X |
||||||||||||
32.1 |
— |
— |
— |
X |
||||||||||||
32.2 |
— |
— |
— |
X |
||||||||||||
101.SCH |
Inline XBRL Taxonomy Extension Schema Document |
— |
— |
— |
X |
|||||||||||
101.CAL |
Inline XBRL Taxonomy Extension Calculation Linkbase Document |
— |
— |
— |
X |
|||||||||||
101.DEF |
Inline XBRL Taxonomy Extension Definition Linkbase Document |
— |
— |
— |
X |
|||||||||||
101.LAB |
Inline XBRL Taxonomy Extension Label Linkbase Document |
— |
— |
— |
X |
101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | X |
||||||||||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | X |
* | Schedules and exhibits to this Exhibit omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request. |
† | Certain portions of this Exhibit have been omitted pursuant to Item 601(b)(2) of Regulation S-K. |
†† | Certain portions of this Exhibit have been omitted pursuant to Item 601(b)(10) of Regulation S-K. |
+ | Management contract or compensatory plan or arrangement. |
TPCO Holding Corp. | ||||||
Date: March 31, 2022 | By: | /s/ Troy Datcher | ||||
Troy Datcher | ||||||
Chief Executive Officer |
Name |
Title |
Date | ||
/s/ Troy Datcher |
Chief Executive Officer | March 31, 2022 | ||
Troy Datcher |
( Principal Executive Officer |
|||
/s/ Mike Batesole |
Chief Financial Officer | March 31, 2022 | ||
Mike Batesole |
( Principal Financial and Accounting Officer |
|||
/s/ Michael Auerbach |
Chairman | March 31, 2022 | ||
Michael Auerbach |
||||
/s/ Jeffry Allen |
Director | March 31, 2022 | ||
Jeffry Allen |
||||
/s/ Carol Bartz |
Director | March 31, 2022 | ||
Carol Bartz |
||||
/s/ Al Foreman |
Director | March 31, 2022 | ||
Al Foreman |
||||
/s/ Leland Hensch |
Director | March 31, 2022 | ||
Leland Hensch |
||||
/s/ Daniel Neukomm |
Director | March 31, 2022 | ||
Daniel Neukomm |
||||
/s/ Desiree Perez |
Director | March 31, 2022 | ||
Desiree Perez |
Toronto, Canada | Chartered Professional Accountants | |
March 31, 2022 |
Licensed Public Accountants |
As at |
Note | December 31, 2021 |
December 31, 2020 | |||||||||
Assets |
||||||||||||
Current |
||||||||||||
Cash |
$ |
165,310,609 |
$ | — | ||||||||
Restricted cash and restricted cash equivalents |
4(c) | 9,581,689 |
582,622,025 | |||||||||
Accounts receivable, net |
32 | 4,705,563 |
— | |||||||||
Income tax receivable |
|
|
|
|
|
|
1,322,340 |
|
|
|
— |
|
Inventory |
6 | 27,239,651 |
— | |||||||||
Prepaid expenses |
5 | 5,895,888 |
— | |||||||||
Notes and other receivables, net |
7 | 4,732,617 |
24,977,765 |
|||||||||
Indemnification assets |
6,044,155 |
— | ||||||||||
|
|
|
|
|||||||||
Total current asset s |
224,832,512 |
607,599,790 | ||||||||||
|
|
|
|
|||||||||
Investments at fair value through profit and loss |
8 | 1,908,524 |
— | |||||||||
Investment in non-marketable securities |
14 | 591,545 |
— | |||||||||
Security deposits |
1,119,754 |
— | ||||||||||
Prepaid expenses and other assets |
756,968 |
81,333 | ||||||||||
Property and equipment |
9 | 23,047,265 |
— | |||||||||
Right-of-use |
13 | 28,364,286 |
— | |||||||||
Right-of-use |
13 | 24,639,605 |
— | |||||||||
Goodwill and intangibles |
10 | 266,194,530 |
— | |||||||||
|
|
|
|
|||||||||
Total assets |
$ |
571,454,989 |
$ | 607,681,123 | ||||||||
|
|
|
|
|||||||||
Liabilities |
||||||||||||
Current |
||||||||||||
Accounts payable and accrued liabilities |
12 | $ |
41,625,317 |
$ | 28,321,972 | |||||||
Consideration payable – current portion |
7,496,240 |
— | ||||||||||
Operating lease liability – current portion |
13 | 3,441,710 |
— | |||||||||
Finance lease liability – current portion |
13 | 13,712 |
— | |||||||||
Cash settled share-based payments |
19 | 5,166,666 |
— | |||||||||
Contingent consideration |
32 | 943,131 |
— | |||||||||
|
|
|
|
|||||||||
Total current liabilities |
58,686,776 |
28,321,972 | ||||||||||
|
|
|
|
|||||||||
Operating lease liabilities |
13 | 27,786,545 |
— | |||||||||
Finance lease liabilities |
13 | 36,774,714 |
— | |||||||||
Consideration payable |
34 |
1,827,515 |
||||||||||
Deferred tax liabilities |
24 | 43,847,866 |
— | |||||||||
|
|
|
|
|||||||||
Total liabilities |
168,923,416 |
28,321,972 | ||||||||||
|
|
|
|
|||||||||
Mezzanine equity |
||||||||||||
Class A Restricted Voting S hare , no par value; unlimited Class A restricted voting ss hare authorized, 57,500,000 issued and outstanding at December 31, 2020 |
18 | — | 582,622,025 | |||||||||
Subscription receipts |
18 | — | 25,087,000 | |||||||||
Redeemable non-controlling interest |
18 | 41,456,387 | — | |||||||||
|
|
|
|
|||||||||
Total mezzanine equity |
41,456,387 |
607,709,025 | ||||||||||
|
|
|
|
|||||||||
S hare holders’ (deficit) equity |
||||||||||||
Class B s hare , no par value; d Class B s shares authorized, nil issued and outstanding at December 31, 2021 and 15,218,750 December 31, 2020 |
20 | — | — | |||||||||
Common s hare , no par value, Common s shares authorized, 97,065,092 issued and outstanding at December 31, 2021 and nil at December 31, 2020 |
20 | — | — | |||||||||
Additional paid in capital |
954,102,859 |
(21,886,268 | ) | |||||||||
Accumulated (deficit) |
(593,027,673 |
) |
(6,463,606 | ) | ||||||||
|
|
|
|
|||||||||
Total shareholders’ (deficit) equity |
361,075,186 |
(28,349,874 | ) | |||||||||
|
|
|
|
|||||||||
Total liabilities, mezzanine equity and shareholders’ (deficit) equity |
$ |
571,454,989 |
$ | 607,681,123 | ||||||||
|
|
|
|
Note |
December 31, 2021 |
December 31, 2020 |
||||||||||
Sales, net of discounts |
4(m) | $ |
173,414,881 |
$ | — | |||||||
Cost of sales |
153,182,191 |
— | ||||||||||
Gross profit |
20,232,690 |
— | ||||||||||
Impairment loss |
16 | 654,317,300 |
— | |||||||||
Operating expenses |
25 | 184,433,403 |
8,813,918 | |||||||||
Loss from operations |
(818,518,013 |
) |
(8,813,918 | ) | ||||||||
Other income (expense) |
||||||||||||
Interest income |
1,244,606 |
2,350,312 | ||||||||||
Interest expense |
27 | (5,183,817 |
) |
— | ||||||||
Gain on debt forgiveness |
15 | 3,358,686 |
— | |||||||||
Loss on disposal of assets |
26 | (2,447,985 |
) |
— | ||||||||
Change in fair value of investments at fair value through profit or loss |
8 | (1,250,990 |
) |
— | ||||||||
Change in fair value of contingent consideration |
32 | 229,819,070 |
— | |||||||||
Other income |
3,573,557 |
— | ||||||||||
229,113,127 |
2,350,312 | |||||||||||
Loss before income taxes |
(589,404,886 |
) |
(6,463,606 | ) | ||||||||
Income tax recovery |
24 | 2,372,552 |
— | |||||||||
Loss and comprehensive loss |
$ |
(587,032,334 |
) |
$ | (6,463,606 | ) | ||||||
Loss and comprehensive loss attributable to shareholders of the company |
$ |
(587,060,124 |
) |
$ | — | |||||||
Loss and comprehensive loss attributable to redeemable non-controlling interest |
$ |
27,790 |
$ | (6,463,606 | ) | |||||||
Loss and comprehensive loss |
$ |
(587,032,334 |
) |
$ |
(6,463,606 |
) | ||||||
Loss per share |
||||||||||||
Basic and diluted |
23 | $ |
(6.18 |
) |
$ | (1.90 | ) | |||||
Weighted average number of common shares |
||||||||||||
Basic and diluted |
23 | 95,006,080 |
15,218,750 |
Number of |
||||||||||||||||||||||||||||||
Note |
Common Shares |
Warrants |
Class B Shares |
Common Shares to be Issued |
Additional Paid in Capital |
Accumulated Deficit |
Total |
|||||||||||||||||||||||
Balance, December 31, 2019 |
— | 35,837,500 | 15,218,750 | — | $ | 589,044 | $ |
— | $ |
589,044 |
||||||||||||||||||||
Net loss |
— | — | — | — | — | (6,463,606 | ) | (6,463,606 |
) | |||||||||||||||||||||
Adjustment to mezzanine equity |
18 | — | — | — | — | (22,475,312 | ) | — | (22,475,312 |
) | ||||||||||||||||||||
Balance December 31, 2020 |
— | 35,837,500 | 15,218,750 | — | (21,886,268 | ) | (6,463,606 | ) | (28,349,874 |
) | ||||||||||||||||||||
Conversion to Class B shares |
20 | 14,655,547 | — | (14,655,547 | ) | — | — | — | — |
|||||||||||||||||||||
Founders’ s hares forfeited |
20 | — | — | (563,203 | ) | — | (496,057 | ) | 496,057 | — |
||||||||||||||||||||
S hares issued in a private placement |
20 | 6,313,500 | — | — | — | 63,135,000 | — | 63,135,000 |
||||||||||||||||||||||
Conversion of Class A restricted voting shares |
20 | 31,407,336 | — | — | — | 318,303,338 | — | 318,303,338 |
||||||||||||||||||||||
S hares issued for long-term strategic contracts |
19, 20 | 2,376,425 | — | — | — | 25,000,000 | — | 25,000,000 |
||||||||||||||||||||||
S hares issued in the Qualifying Transaction |
20 | 42,891,175 | — | — | 272,104 | 546,447,112 | — | 546,447,112 |
||||||||||||||||||||||
S hares issued to extinguish liabilities in the Qualifying Transaction |
20 | 336,856 | — | — | — | 4,264,597 | — | 4,264,597 |
||||||||||||||||||||||
S hares to be issued to settle contingent consideration |
32 | 24,584 | — | — | 309,284 | 1,957,045 | — | 1,957,045 |
||||||||||||||||||||||
Contingent s hares to be issued in the Qualifying Transaction |
3 | — | — | — | 187,380 | 2,372,231 | — | 2,372,231 |
||||||||||||||||||||||
Contingent s hares issued in the Qualifying Transaction |
20 |
25,000 |
— | — | (25,000 |
) |
— | — | — |
|||||||||||||||||||||
Replacement options issued in a business acquisition |
3 |
— | — | — | — | 3,489,501 | — | 3,489,501 |
||||||||||||||||||||||
S hares issued to acquire Calma |
20 |
458,898 |
— | — | — | 1,468,474 |
— | 1,468,474 |
||||||||||||||||||||||
S hares repurchased under share repurchase agreements |
17, 20 | (1,725,000 | ) | — | — | — | (7,055,250 | ) | — | (7,055,250 |
) | |||||||||||||||||||
S hares repurchased under NCIB |
20 | (157,600 | ) | — | — | — | (603,165 | ) | — | (603,165 |
) | |||||||||||||||||||
S hares issued for options exercised |
22 | 3,313 | — | — | — | 12,972 | — | 12,972 |
||||||||||||||||||||||
S hares issued for RSUs vested |
20, 22 | 455,058 | — | — | — | — | — | — |
||||||||||||||||||||||
Tax settlements associated with RSUs |
22 | — | — | — | — | (1,080,071 | ) | — | (1,080,071 |
) | ||||||||||||||||||||
Modification of RSUs |
22 | — | — | — | — | 3,451,365 | — | 3,451,365 |
||||||||||||||||||||||
S hares -based compensation |
22 | — | — | — | — | 15,322,035 | — | 15,322,035 |
||||||||||||||||||||||
Net loss attributable to shareholders of the Company |
— | — | — | — | — | (587,060,124 | ) | (587,060,124 |
) | |||||||||||||||||||||
Balance December 31, 2021 |
97,065,092 | 35,837,500 | — | 743,768 | $ | 954,102,859 | $ |
(593,027,673 | ) | $ |
361,075,186 |
|||||||||||||||||||
Note |
December 31, 2021 |
December 31, 2020 |
||||||||||
Cash provided by (used in) |
||||||||||||
Operating activities |
||||||||||||
Net loss |
$ |
(587,032,334 |
) |
$ | (6,463,606 | ) | ||||||
Adjustments for items not involving cash |
||||||||||||
Impairment loss |
16 | 654,317,300 |
— | |||||||||
Non-cash interest income |
(1,149,041 |
) |
— | |||||||||
Interest expense |
27 | 5,183,817 |
— | |||||||||
Provision for bad debts |
32 | 2,016,191 |
— | |||||||||
Provision for note receivable |
7 | 2,660,943 |
— | |||||||||
Loss on disposal of assets |
26 | 2,447,985 |
— | |||||||||
Gain on debt forgiveness |
15 | (3,358,686 |
) |
— | ||||||||
Fair value change of investments at fair value through profit or loss |
8 | 1,250,990 |
— | |||||||||
Non-cash operating lease expense |
13 | 4,956,969 |
— | |||||||||
Depreciation and amortization |
25 | 27,615,762 |
— | |||||||||
S hare issued for long-term strategic contracts |
19 | 25,000,000 |
— | |||||||||
S hare -based compensation expense, net of withholding tax settlement |
19,663,385 |
— | ||||||||||
Non-cash marketing expense |
19 | 5,166,666 |
— | |||||||||
Fair value change of contingent consideration |
32 | (229,819,070 |
) |
— | ||||||||
Deferred income tax recovery |
24 | (5,590,409 |
) |
— | ||||||||
Repayment of operating lease liabilities |
(5,190,663 |
) |
||||||||||
Net changes in non-cash working capital items |
28 | (46,513,086 |
) |
8,813,918 | ||||||||
|
|
|
|
|||||||||
Total operating activities |
(128,373,281 |
) |
2,350,312 | |||||||||
|
|
|
|
|||||||||
Financing activities |
||||||||||||
Proceeds from private placement |
18, 20 | 51,635,000 |
— | |||||||||
Redemption of Class A restricted voting s hares |
(264,318,686 |
) |
— | |||||||||
Proceeds from exercise of options |
22 | 12,972 |
— | |||||||||
Repayment of consideration payable |
(1,034,417 |
) |
— | |||||||||
Repayment of finance lease liabilities |
(4,385,528 |
) |
— | |||||||||
Repurchase of s hares |
17, 20 | (6,542,196 |
) |
— | ||||||||
Repayment of line of credit |
(1,000,000 |
) |
— | |||||||||
|
|
|
|
|||||||||
Total financing activities |
(225,632,855 |
) |
— | |||||||||
|
|
|
|
|||||||||
Investing activities |
||||||||||||
Net cash paid in the Qualifying Transaction |
3 | (28,143,886 |
) |
— | ||||||||
Net cash paid in business combinations |
11 | (20,612,867 |
) |
— | ||||||||
Purchases of property and equipment |
9 | (9,760,359 |
) |
— | ||||||||
Advances for note receivable |
7 | (5,650,000 |
) |
— | ||||||||
Advances for investments at fair value through profit or loss |
8 | (1,000,000 |
) |
— | ||||||||
Proceeds from notes receivable |
7 | 374,984 |
— | |||||||||
Proceeds from sale of net assets |
26 | 11,068,537 |
— | |||||||||
|
|
|
|
|||||||||
Total investing activities |
(53,723,591 |
) |
— | |||||||||
|
|
|
|
|||||||||
Net change in cash during the period |
(407,729,727 |
) |
2,350,312 | |||||||||
Cash, restricted cash and rest cash equivalentsr icted Beginning of period |
$ |
582,622,025 |
$ | 580,271,713 | ||||||||
|
|
|
|
|||||||||
End of period |
$ |
174,892,298 |
$ | 582,622,025 | ||||||||
|
|
|
|
|||||||||
Cash |
165,310,609 |
— | ||||||||||
Restricted cash and restricted cash equivalents |
9,581,689 |
582,622,025 | ||||||||||
|
|
|
|
|||||||||
Cash, restricted cash and restricted cash equivalents |
$ |
174,892,298 |
$ | 582,622,025 | ||||||||
|
|
|
|
i) |
Basis of consolidation |
ii) |
Variable interest entities (“VIEs”) |
Subsidiaries |
Jurisdiction of incorporation |
Ownership interest December 31, 2021 |
Ownership interest December 31, 2020 |
|||||||||
TPCO US Holding LLC |
Delaware | 100 | % | 100 | % | |||||||
Social Equity Ventures LLC |
California | 100 | % | — | ||||||||
CMG Partners, Inc. |
Delaware | 100 | % | — | ||||||||
well. By Caliva LLC |
California | 100 | % | — | ||||||||
well. By Caliva Centers |
California | 100 | % | — | ||||||||
well. By Caliva e-commerce, LLC |
California | 100 | % | — | ||||||||
Live Zola, LLC |
California | 100 | % | — | ||||||||
NC3 Systems, Inc. |
California | 100 | % | — | ||||||||
NC4 Systems, Inc. |
California | 100 | % | — | ||||||||
NC5 Systems, Inc. |
California | 100 | % | — | ||||||||
NC6 Systems, Inc. |
California | 100 | % | — | ||||||||
Caliva CADECC1, LLC |
California | 100 | % | — | ||||||||
Caliva CARERC1, LLC |
California | 100 | % | — | ||||||||
Caliva CAMISJ2, Inc. |
California | 100 | % | — | ||||||||
OG California Branding, Inc. |
California | 100 | % | — | ||||||||
Caliva CAREDELA1, LLC |
California | 42 | % | — | ||||||||
G & C Staffing, LLC |
California | 100 | % | — | ||||||||
Fresh Options, LLC |
California | 100 | % | — | ||||||||
Alpha Staffing, LLC |
California | 100 | % | — | ||||||||
Caliva CAREWH1, LLC |
California | 100 | % | — | ||||||||
Caliva CARECE1, LLC |
California | 100 | % | — | ||||||||
Caliva CADESA1, LLC |
California | 100 | % | — | ||||||||
Caliva CADEEM1, LLC |
California | 100 | % | — | ||||||||
Caliva CAREST1, LLC |
California | 100 | % | — | ||||||||
Caliva MSA, LLC |
California | 100 | % | — | ||||||||
Coast L Acquisition Corp |
California | 100 | % | — | ||||||||
Martian Delivery, LLC |
California | 100 | % | — | ||||||||
Kase’s Journey, Inc. |
California | 100 | % | — | ||||||||
Calma WeHo LLC |
California | 85 | % | — | ||||||||
Coastal Holding Company, LLC 1 |
California | 0 | % | — | ||||||||
Coastal Dispensary, LLC 1 |
California | 0 | % | — | ||||||||
Coastal Delivery Service, LLC 1 |
California | 0 | % | — | ||||||||
Coastal Retail Lompoc, LLC 1 |
California | 0 | % | — | ||||||||
Southern California Collective, Inc. 1 |
California | 0 | % | — | ||||||||
Releaf Alternative Inc. 1 |
California | 0 | % | — | ||||||||
Coastal Retail Concord, LLC 1 |
California | 0 | % | — | ||||||||
Coastal Delivery SLO, LLC 1 |
California | 0 | % | — | ||||||||
Varda Inc. 1 |
California | 9.5 | % | — | ||||||||
Left Coast Ventures, Inc. |
Delaware | 100 | % | — | ||||||||
Sturdivant Ventures, LLC |
California | 100 | % | — | ||||||||
LCV Holdings, HMB, LLC |
California | 100 | % | — | ||||||||
Rever Holdings, LLC |
California | 100 | % | — | ||||||||
Eko Holdings, LLC |
California | 100 | % | — | ||||||||
Lief Holdings, LLC |
California | 100 | % | — | ||||||||
LCV Holdings SISU 710, LLC |
California | 100 | % | — | ||||||||
SISU Extraction, LLC |
California | 100 | % | — | ||||||||
Fluid South, Inc. |
California | 100 | % | — | ||||||||
Capitol Cocoa, Inc. |
California | 100 | % | — |
1 |
The Company has determined that it is the primary beneficiary of these variable interest entities. Refer to Notes 11 and 34 for further details. |
iii) |
Use of estimates |
iv) |
Emerging growth company |
Caliva/OGE |
LCV |
SISU |
Total |
|||||||||||||
Total consideration transferred (i) |
$ | 619,766,731 | $ | 120,651,941 | $ | 92,188,146 | $ |
832,606,818 |
||||||||
|
|
|
|
|
|
|
|
|||||||||
Assets acquired |
||||||||||||||||
Cash, restricted cash and restricted cash equivalents |
11,164,957 | 3,022,262 | 976,906 | 15,164,125 |
||||||||||||
Accounts receivable |
2,006,699 | 1,090,811 | 1,022,532 | 4,120,042 |
||||||||||||
Inventory |
11,910,959 | 6,258,063 | 5,580,258 | 23,749,280 |
||||||||||||
Prepaid expenses |
3,589,808 | 215,938 | 82,701 | 3,888,447 |
||||||||||||
Indemnification assets |
2,199,029 | 2,000,000 | — | 4,199,029 |
||||||||||||
Property and equipment |
7,785,157 | 3,305,145 | 1,163,902 | 12,254,204 |
||||||||||||
Intangible assets |
187,600,000 | 20,740,000 | 46,200,000 | 254,540,000 |
||||||||||||
Right-of-use assets – operating |
12,115,573 | 4,461,809 | 880,863 | 17,458,245 |
||||||||||||
Right-of-use assets – finance |
26,176,837 | — | — | 26,176,837 |
||||||||||||
Investment in associate |
— | 6,500,000 | — | 6,500,000 |
||||||||||||
Investment in non-marketable securities |
591,545 | — | — | 591,545 |
||||||||||||
Security deposits and other |
869,238 | 137,051 | 34,175 | 1,040,464 |
||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total assets acquired |
266,009,802 | 47,731,079 | 55,941,337 | 369,682,218 |
||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Liabilities assumed |
||||||||||||||||
Accounts payable and accrued liabilities |
26,130,222 | 14,817,802 | 8,242,144 | 49,190,168 |
||||||||||||
Consideration payable |
2,458,844 | 2,972,782 | — | 5,431,626 |
||||||||||||
Loans payable |
3,060,250 | 298,436 | — | 3,358,686 |
||||||||||||
Line of credit |
— | — | 1,000,000 | 1,000,000 |
||||||||||||
Deferred tax liability |
35,483,327 | 4,199,766 | — | 39,683,093 |
||||||||||||
Lease liabilities |
49,746,261 | 4,461,809 | 1,183,451 | 55,391,521 |
||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total liabilities assumed |
116,878,904 | 26,750,595 | 10,425,595 | 154,055,094 |
||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Goodwill |
$ | 470,635,833 | $ | 99,671,457 | $ | 46,672,404 | $ |
616,979,694 |
||||||||
|
|
|
|
|
|
|
|
(i) | Total consideration transferred is comprised of the following: |
Caliva/OGE |
LCV |
SISU |
Total |
|||||||||||||
Upfront consideration |
||||||||||||||||
Cash |
$ | 465,140 | $ | 177,970 | $ | 11,089,535 | $ |
11,732,645 |
||||||||
Liabilities settled in cash as part of the Qualifying Transaction |
12,614,773 | 15,400,000 | 3,560,593 | 31,575,366 |
||||||||||||
Liabilities settled in shares as part of the Qualifying Transaction |
— | — | 4,264,597 | 4,264,597 |
||||||||||||
Common s hares |
408,178,567 | 57,529,825 | 63,581,153 | 529,289,545 |
||||||||||||
Common s hares to be issued |
1,567,549 | 5,897,750 | 9,692,268 |
17,157,567 |
||||||||||||
Consideration payable |
1,000 | 5,120 | — | 6,120 |
||||||||||||
Contingent consideration (liability) – Trading price consideration |
191,077,970 | 41,641,276 | — | 232,719,246 |
||||||||||||
Contingent consideration (liability) – Other |
— | — | — | — |
||||||||||||
Contingent consideration (equity) |
2,372,231 | — | — | 2,372,231 |
||||||||||||
Replacement options |
3,489,501 | — | — | 3,489,501 |
||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total consideration transferred |
$ | 619,766,731 | $ | 120,651,941 | $ | 92,188,146 | $ |
832,606,818 |
||||||||
|
|
|
|
|
|
|
|
a) | Trading price consideration Caliva and OGE shareholders received a contingent right for up to 18,356,299 additional common shares (the “pool of common shares ”) in the event the 20-day volume weighted average trading price (“VWAP”) of the common shares reaches $13.00, $17.00 and $21.00 within three years of closing, with one-third issuable upon the achievement of each price threshold, respectively. The pool of common shares is to be shared with Caliva option holders who were employees of Caliva at the time of the transaction (“Caliva employee option holders”). In order to receive their share of the contingent consideration, Caliva employee option holders must be employed by the Company at the time the contingent consideration is paid out. The portion of the pool of common shares that may be paid to Caliva employee option holders is being accounted for as employee share-based compensation and is being expensed over the estimated vesting period. The portion of the pool of common shares that may be paid to former Caliva and OGE shareholders is being accounted for as contingent consideration in the amount of $191,077,970 and is included in the consideration transferred above. Refer to Note 32 for further details. |
b) | Earn-out shares share holders received a contingent right for up to 3,929,327 additional common shares if the aggregate consolidated cash of the Company at closing, net of short-term indebtedness, was less than $225,000,000. As the consolidated cash at the time of closing was above this amount, no additional common shares will be issued, and no value has been attributed to this in the transaction. |
c) | Other shares related to U.S. Paycheck Protection Program (“PPP”) loans. The fair value associated with the contingent consideration at the transaction date was nil. Refer to Note 32 for further details. |
d) | 187,380 shares of TPCO have been placed into escrow and will be issued when subsidiaries of Caliva receive their licenses. This is presented as contingent shares to be issued in equity. If the licenses are not obtained, the shares will be issued to Caliva former share holders, and therefore have been included as part of consideration. Refer to Note 20 for further details. |
a) | Trading price consideration share holders will have a contingent right for up to 3,856,955 additional common shares in the event the 20-day VWAP of the common shares reaches $13.00, $17.00 and $21.00 within three years of closing, with one-third issuable upon the achievement of each price threshold, respectively. The fair value of the contingent consideration on January 15, 2021 was $41,641,276 and is included in consideration transferred above. Refer to Note 32 for further details. |
b) | Other shares that are contingent on the outcome of certain events. The fair value associated with the contingent consideration at the transaction date is nil. Refer to Note 32 for further details. |
Leasehold improvements |
Shorter of lease term or estimated useful life | |||
Production equipment |
1 - 7 years | |||
Furniture and fixtures |
2 - 7 years |
|||
Office equipment |
2 - 7 years | |||
Vehicles |
3 - 7 years | |||
Building |
30 years |
License |
Greater of lease term or estimated useful life | |||
Cultivation network |
7 years | |||
Brand |
5 – 20 years | |||
Customer relationship |
9 years |
December 31, 2021 |
||||
Direct to consumer |
$ |
54,238,607 |
||
Wholesale |
119,176,274 |
|||
|
|
|||
$ |
173,414,881 |
|||
|
|
• | Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities; |
• | Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and |
• | Level 3: one or more significant inputs used in a valuation technique are unobservable in determining fair values of the asset or liability. |
• |
From the customer’s perspective, the only party they interact with is the Company. The customer does not know the origin of the product and there is no brand recognition associated with the product (i.e., the products do not carry a brand name, and instead the labels only carry information with respect to the contents of the package). |
• |
If the customer returns the product, the Company will decide whether to take the product back and refund the customer, and the Company will have no right to compensation from the supplier. As a result, the Company has back-end inventory risk. |
• |
The Company has discretion in setting prices and in many cases the supplier does not know the amount the Company sold the products for. |
December 31, 2021 |
December 31, 2020 |
|||||||
Prepaid expenses |
$ |
109,929 |
$ | — | ||||
Prepaid insurance |
1,560,840 |
— | ||||||
Prepaid inventory |
2,188,881 |
— | ||||||
Other prepaid assets |
2,036,238 |
— | ||||||
|
|
|
|
|||||
$ |
5,895,888 |
$ | — | |||||
|
|
|
|
December 31, 2021 |
December 31, 2020 |
|||||||
Packaging supplies |
$ |
2,784,846 |
$ | — | ||||
Biological assets |
1,371,749 |
— | ||||||
Raw materials |
2,284,344 |
— | ||||||
Work in progress |
3,445,426 |
— | ||||||
Finished goods |
17,353,286 |
— | ||||||
|
|
|
|
|||||
$ |
27,239,651 |
$ | — | |||||
|
|
|
|
December 31, 2021 |
December 31, 2020 |
|||||||
Upfront payment (i) |
$ |
5,650,000 |
$ | — | ||||
Promissory note receivable (ii) |
543,560 |
— | ||||||
Other receivable (iii) |
1,200,000 |
— | ||||||
Receivable from Sponsor (iv) |
— |
24,977,765 | ||||||
|
|
|
|
|||||
Total notes receivable |
7,393,560 |
24,977,765 | ||||||
Less allowance for credit losses (i) |
(2,660,943 |
) |
— |
|||||
|
|
|
|
|||||
Note receivable |
$ |
4,732,617 |
$ | 24,977,765 | ||||
|
|
|
|
(i) | In May 2021, the Company entered into a series of arrangements to obtain the rights to four acres of land that is licensed for outdoor grow (the “Arrangement”). The purchase price for the Arrangement is $6,000,000 in cash (subject to holdbacks), shares with an estimated value of $2,500,000 to be issued when the transaction closes and up to 1,309,263 shares subject to earnouts. The upfront payment of $5,650,000, net of holdbacks of $350,000, is secured by a non-interest-bearing promissory note. The holdback amount will be paid on the first anniversary of the closing of the transaction. The closing of the transaction is dependent on the satisfaction of various conditions, which have not been met to date. In the event that the transaction does not close, the promissory note will be repaid to the Company. The outstanding balance of this note matures and is due and payable in full on the earlier of June 1, 2022 or five business days after the termination of the transaction. As there is uncertainty as to whether the transaction will close, the Company recorded an allowance for credit losses of $2,660,943 related to the upfront payment. |
(ii) | During the year ended December 31, 2021, the Company disposed of its non-THC business. As part of the proceeds received, the Company entered into a promissory note. The note is unsecured, bearing interest at 2% per annum and payable in 5 equal quarterly instalments beginning on July 31, 2021. During the year ended December 31, 2021, the Company received $374,984 representing two payments. |
(iii) | During the year ended December 31, 2021, the Company was successful in a legal matter and agreed to a settlement of $2,200,000, of which $1,000,000 was received prior to December 31, 2021. The remaining settlement is to be received in full by December 2022 based on an agreed upon payment schedule. |
(iv) | As at December 31, 2020, other receivable was comprised of a cash account held by the Subversive Capital Sponsor LLC (the “Sponsor”) for the benefit of the Company. During the year ended December 31, 2021, the private placement closed, and the cash account held by the Sponsor was transferred to the Company. |
Level 1 |
Level 3 |
Total |
||||||||||
Balance, January 1, 2021 |
$ | — | $ | — | $ |
— |
||||||
Acquired in the period |
2,159,514 | 1,000,000 | 3,159,514 |
|||||||||
Change in fair value |
(1,299,018 | ) | 48,028 | (1,250,990 |
) | |||||||
|
|
|
|
|
|
|||||||
Balance, December 31, 2021 |
$ |
860,496 |
$ |
1,048,028 |
$ |
1,908,524 |
||||||
|
|
|
|
|
|
Leasehold improvements |
Production equipment |
Furniture and fixtures |
Vehicles |
Office equipment |
Building |
Total |
||||||||||||||||||||||
Gross carrying amount |
||||||||||||||||||||||||||||
Balance, December 31, 2020 |
$ | — | $ | — | $ | — | $ | — | $ | — | $ | — | $ |
— |
||||||||||||||
Acquired in the Qualifying Transaction (Note 3) |
7,776,866 | 3,053,047 | 436,963 | 372,774 | 614,554 | — | 12,254,204 |
|||||||||||||||||||||
Acquired in a business combination (Note 11) |
4,509,125 | 207,756 | 355,564 | 117,996 | 122,777 | — | 5,313,218 |
|||||||||||||||||||||
Additions |
1,903,466 | 630,589 | 119,227 | 198,410 | 359,178 | 6,549,489 | 9,760,359 |
|||||||||||||||||||||
Disposals |
(327,700 | ) | (368,479 | ) | (52,895 | ) | — | (31,509 | ) | — | (780,583 |
) | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance, December 31, 2021 |
$ | 13,861,757 | $ | 3,522,913 | $ | 858,859 | $ | 689,180 | $ | 1,065,000 | $ | 6,549,489 | $ |
26,547,198 |
||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Depreciation |
||||||||||||||||||||||||||||
Balance, December 31, 2020 |
$ | — | $ | — | $ | — | $ | — | $ | — | $ | — | $ |
— |
||||||||||||||
Additions |
1,760,781 | 1,251,920 | 198,127 | 115,919 | 213,454 | 81,866 | 3,622,067 |
|||||||||||||||||||||
Disposals |
(19,934 | ) | (101,550 | ) | (650 | ) | — | — | — | (122,134 |
) | |||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance, December 31, 2021 |
$ | 1,740,847 | $ | 1,150,370 | $ | 197,477 | $ | 115,919 | $ | 213,454 | $ | 81,866 | $ |
3,499,933 |
||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Carrying amount December 31, 2020 |
$ |
— |
$ |
— |
$ |
— |
$ |
— |
$ |
— |
— |
$ |
— |
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Carrying amount December 31, 2021 |
$ |
12,120,910 |
$ |
2,372,543 |
$ |
661,382 |
$ |
573,261 |
$ |
851,546 |
$ |
6,467,623 |
$ |
23,047,265 |
||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Goodwill |
License |
Cultivation Network |
Brand |
Customer Relationship |
Total |
|||||||||||||||||||
Gross carrying amount |
||||||||||||||||||||||||
Balance, December 31, 2020 |
$ | — | $ | — | $ | — | $ | — | $ | — | $ |
— |
||||||||||||
Acquired in the Qualifying Transaction (Note 3) |
616,979,694 | 137,460,000 | 5,020,000 | 109,140,000 | 2,920,000 | 871,519,694 |
||||||||||||||||||
Acquired in a business combination (Note 11) |
45,666,784 | 21,387,210 | — | 12,040,360 | — | 79,094,354 |
||||||||||||||||||
Impairment (Note 16) |
(615,589,438 | ) | (33,486,917 | ) | (3,515,000 | ) | — | — | (652,591,355 |
) | ||||||||||||||
Transferred to assets held for sale (Note 16) |
— | (400,000 | ) | — | — | (400,000 |
) | |||||||||||||||||
Disposals |
(3,005,395 | ) | (250,000 | ) | — | (4,480,000 | ) | — | (7,735,395 |
) | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Balance, December 31, 2021 |
$ | 44,051,645 | $ | 124,710,293 | $ | 1,505,000 | $ | 116,700,360 | $ | 2,920,000 | $ |
289,887,298 |
||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Amortization |
||||||||||||||||||||||||
Balance, December 31, 2020 |
$ | — | $ | — | $ | — | $ | — | $ | — | $ |
— |
||||||||||||
Additions |
— | 17,604,713 | 547,594 | 5,264,606 | 308,424 | 23,725,337 |
||||||||||||||||||
Impairment (Note 16) |
— | (32,569 | ) | — | (32,569 |
) | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Balance, December 31, 2021 |
$ | — | $ | 17,572,144 | $ | 547,594 | $ | 5,264,606 | $ | 308,424 | $ |
23,692,768 |
||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Carrying amount December 31, 2020 |
$ |
— |
$ |
— |
$ |
— |
$ |
— |
$ |
— |
$ |
— |
||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Carrying amount December 31, 2021 |
$ |
44,051,645 |
$ |
107,138,149 |
$ |
957,406 |
$ |
111,435,754 |
$ |
2,611,576 |
$ |
266,194,530 |
||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
Estimated Amortization |
||||
2022 |
$ |
23,001,409 |
||
2023 |
15,663,355 |
|||
2024 |
15,450,848 |
|||
2025 |
15,344,561 |
|||
2026 |
14,894,456 |
|||
Thereafter |
137,788,256 |
|||
|
|
|||
$ |
222,142,885 |
|||
|
|
Asset |
Discount Rate |
Forecasted Sales Growth Rate |
Terminal Value Growth Rate | |||
Licenses |
15.5% - 20.5% |
Average of -4% to 24% |
3% | |||
Cultivation Network |
20.5% | Average of -42% to 6% |
3% |
Direct-to-consumer |
$ | 470,577,972 | ||
Wholesale – Branded products |
$ | 92,783,625 | ||
Wholesale – Non-branded products |
$ | 46,672,404 |
Reporting unit |
Discount Rate |
Forecasted Sales Growth Rate |
Terminal Value Growth Rate |
|||||||||
DTC |
13.5 | % | Average of 24 | % | 3 | % | ||||||
Wholesale- Branded products |
13.5 | % | Average of 17 | % | 3 | % | ||||||
Wholesale- Non-branded products |
18.5 | % | Average -4 |
% | 3 | % |
Coastal |
Calma |
Other |
Total |
|||||||||||||
Total consideration transferred (i) |
$ |
20,700,000 |
$ |
9,968,474 |
$ |
2,894,952 |
$ |
33,563,426 |
||||||||
Redeemable non-controlling interest |
$ |
39,928,597 |
$ |
1,500,000 |
$ |
— |
$ |
41,428,597 |
||||||||
Assets acquired |
||||||||||||||||
Current assets |
||||||||||||||||
Cash |
$ | — | $ | — | $ | 33,213 | $ | 33,213 |
||||||||
Restricted cash |
|
|
9,989,470 |
|
|
|
— |
|
|
|
— |
|
|
|
9,989,470 |
|
Inventory |
2,477,000 | 379,617 | 98,050 | 2,954,667 |
||||||||||||
Prepaid expenses |
515,947 | 109,929 | — | 625,876 |
||||||||||||
Indemnification assets |
980,000 | — | 865,126 | 1,845,126 |
||||||||||||
Long-term assets |
||||||||||||||||
Security deposits |
— | 61,185 | — | 61,185 |
||||||||||||
Property and equipment |
4,839,634 | 457,551 | 16,033 | 5,313,218 |
||||||||||||
Right-of-use assets – operating lease |
12,491,344 | 2,790,377 | 433,934 | 15,715,655 |
||||||||||||
|
26,482,000 |
|
|
|
5,227,000 |
|
|
|
1,718,570 |
|
|
|
33,427,570 |
| ||
Total assets acquired |
57,775,395 |
9,025,659 |
3,164,926 |
69,965,980 |
||||||||||||
Liabilities assumed |
||||||||||||||||
Accounts payable and accrued liabilities |
9,483,665 | 1,115,477 | 1,069,654 | 11,668,796 |
||||||||||||
Consideration payable – current portion |
924,457 | — | — | 924,457 |
||||||||||||
Consideration payable |
2,170,463 | — | — | 2,170,463 |
||||||||||||
Lease liabilities |
12,835,761 | 2,790,377 | 433,934 | 16,060,072 |
||||||||||||
Deferred tax liabilities |
|
|
7,985,746 |
|
|
|
1,449,682 |
|
|
|
381,525 |
|
|
|
9,816,953 |
|
Total liabilities assumed |
33,400,092 |
5,355,536 |
1,885,113 |
40,640,741 |
||||||||||||
Goodwill |
$ |
36,253,294 |
$ |
7,798,351 |
$ |
1,615,139 |
$ |
45,666,784 |
||||||||
(i) Total consideration transferred is comprised of the following: |
|
|
|
|||||||||||||
Coastal |
Calma |
Other |
Total |
|||||||||||||
Cash |
$ | 20,700,000 | $ | 8,500,000 | $ | 1,435,550 | $ | 30,635,550 |
||||||||
Consideration payable |
— | — |
1,459,402 | 1,459,402 |
||||||||||||
Common shares |
— | 1,468,474 | — | 1,468,474 |
||||||||||||
Total consideration |
$ |
20,700,000 |
$ |
9,968,474 |
$ |
2,894,952 |
$ |
33,563,426 |
December 31, 2021 |
December 31, 2020 |
|||||||
Trade payables |
$ |
8,390,991 |
$ | — | ||||
Other accrued expenses |
7,288,466 |
28,321,972 | ||||||
Accrued payroll expenses |
1,326,493 |
— | ||||||
Accrued severance expenses |
1,331,365 |
— | ||||||
Accrued income and other taxes |
19,062,306 |
— | ||||||
Goods received but not yet invoiced |
4,225,696 |
— | ||||||
|
|
|
|
|||||
$ |
41,625,317 |
$ | 28,321,972 | |||||
|
|
|
|
December 31, 2021 |
||||
Operating lease costs |
$ |
4,765,566 |
||
Short term lease expense |
191,403 |
|||
|
|
|||
Lease expense |
4,956,969 |
|||
Finance lease cost: |
||||
Depreciation and amortization of lease assets |
1,619,093 |
|||
Interest on lease liabilities |
4,515,112 |
|||
|
|
|||
Finance lease cost |
6,134,205 |
|||
|
|
|||
Total lease costs |
$ |
11,091,174 |
||
|
|
Operating Lease |
|
Finance Lease |
| |||
Weighted average discount rate |
11.51 |
% |
13.02 |
% | ||
Weighted average remaining lease term (in years) |
9.71 |
|
15.75 |
|
Operating Lease |
Finance Lease |
|||||||
2022 |
$ | 6,774,561 | $ | 4,493,443 | ||||
2023 |
5,662,221 | 4,625,156 | ||||||
2024 |
5,281,010 | 4,763,910 | ||||||
2025 |
5,081,629 | 4,906,828 | ||||||
2026 |
4,647,394 | 5,054,033 | ||||||
Thereafter |
23,921,870 | 64,884,897 | ||||||
|
|
|
|
|||||
Total undiscounted lease liabilities |
51,368,685 | 88,728,267 | ||||||
Interest on lease liabilities |
20,140,430 | 51,939,841 | ||||||
|
|
|
|
|||||
Total present value of minimum lease payments |
31,228,255 | 36,788,426 | ||||||
Lease liability – current portion |
3,441,710 | 13,712 | ||||||
|
|
|
|
|||||
Lease liability |
$ |
27,786,545 |
$ |
36,774,714 |
||||
|
|
|
|
Operating lease |
Finance lease |
|||||||
Gross carrying amount |
||||||||
Balance, December 31, 2020 |
$ | — | $ | — | ||||
Acquired in the Qualifying Transaction (Note 3) |
17,458,245 | $ | 26,176,837 | |||||
Acquired in a business combination (Note 11) |
15,715,655 | — | ||||||
Lease reclassification |
(753,523 | ) | 753,523 | |||||
Reassessment of purchase option and lease term (i) |
— | 5,850,523 | ||||||
Reassessment of lease term |
(405,831 | ) | — | |||||
Impairment (Note 16) |
(275,320 | ) | — | |||||
Transfer to assets held for sale (Note 16) |
(2,215,440 | ) | — | |||||
Transfer from assets held for sale (Note 16) |
1,132,246 | — | ||||||
Additions |
1,139,900 | — | ||||||
Disposals |
(815,131 | ) | (6,522,185 | ) | ||||
|
|
|
|
|||||
Balance, December 31, 2021 |
$ | 30,980,801 | $ | 26,258,698 | ||||
|
|
|
|
|||||
Depreciation |
||||||||
Balance, December 31, 2020 |
$ | — | $ | — | ||||
Additions |
2,616,515 | 1,619,093 | ||||||
|
|
|
|
|||||
Balance, December 31, 2021 |
$ | 2,616,515 | $ | 1,619,093 | ||||
|
|
|
|
|||||
Carrying amount December 31, 2020 |
$ |
— |
$ |
— |
||||
|
|
|
|
|||||
Carrying amount December 31, 2021 |
$ |
28,364,286 |
$ |
24,639,605 |
||||
|
|
|
|
(i) | During the year ended December 31, 2021, the Company determined that it was reasonably certain to exercise its right of first refusal to acquire one of the properties under lease. As a result, the right-of-use as well as to recognize a reduction in the lease term, the impact of which was a net $649,477 reduction in the carrying value. In July 2021, the Company exercised the right of first refusal and acquired the building. |
December 31, 2021 |
December 31, 2020 |
|||||||
Non-THC business (i) |
$ |
5,555,437 |
$ | — | ||||
Assets held for sale (ii) |
1,995,945 |
— | ||||||
Impairment (Note 10) |
646,765,918 |
— | ||||||
|
|
|
|
|||||
$ |
654,317,300 |
$ | — | |||||
|
|
|
|
(i) | In February 2021, the Company became committed to a plan to sell its non-THC business, which was acquired as part of the Caliva and OGE and LCV acquisitions on January 15, 2021 (Note 3). As a result of the decision to sell, the assets were tested for impairment and an impairment loss of $5,555,437 of goodwill was recognized. The disposal group did not represent a separate major line of business, and for that reason it has not been disclosed as discontinued operations for the year ended December 31, 2021. During year ended December 31, 2021, the Company disposed of the non-THC business. Refer to Note 26 for further details. |
(ii) | In May 2021, the Company became committed to a plan to sell three licenses and transfer the associated leases, which were acquired as part of the Caliva and OGE and LCV acquisitions on January 15, 2021 (Note 3). Prior to reclassification to assets held for sale, the assets were tested for impairment. As a result, an impairment loss of $237,431 was recognized on the licenses and $275,320 on the right-of-use assets. One of the licenses was subsequently sold. Refer to Note 26 for further details. |
December 31, 2021 |
December 31, 2020 |
|||||||
Share repurchased |
1,725,000 |
— | ||||||
Average price |
$ |
3.44 |
$ | — | ||||
Aggregate value |
$ |
5,939,031 |
$ | — |
December 31, 2021 |
December 31, 2020 |
|||||||
Redeemable non-controlling interest (i) |
$ |
41,456,387 |
$ | — | ||||
Class A restricted voting shares (ii) |
0 |
582,622,025 | ||||||
Subscription receipts (iii) |
0 |
25,087,000 | ||||||
$ |
41,456,387 |
$ | 607,709,025 | |||||
Coastal Holdings Inc. (a) |
Varda Inc. (b) |
Calma (c) |
Total |
|||||||||||||
Balance, January 1, 2021 |
$ |
— |
$ |
— |
$ |
— |
$ |
— |
||||||||
Acquired in a business combination (Note 11) |
35,428,597 |
4,500,000 |
1,500,000 |
41,428,597 |
||||||||||||
Net (loss) income attributable to redeemable non-controlling interest |
(121,138 |
) |
148,928 |
— |
27,790 |
|||||||||||
Balance, December 31, 2021 |
$ |
35,307,459 |
$ |
4,648,928 |
$ |
1,500,000 |
$ |
41,456,387 |
||||||||
a) |
The Company is obligated to acquire 100% of the equity in Coastal Holdings Inc. when the transaction closes, which is contingent upon various conditions including approval for licenses to transfer in seven (7) locations. As at December 31, 2021, the number of shares that would be required to redeem the NCI is approximately 21,421,251. |
b) |
The Company is obligated to acquire the remaining 90.5% of Varda Inc. when regulatory approval is received for the license to transfer for $4,500,000 to be settled in cash. The carrying amount of the NCI includes income allocation as per the agreement. |
c) |
The Company is obligated to acquire the Class A shares of Calma when regulatory approval is received for the license to transfer. The Calma NCI will be redeemed for a variable number of shares to the value of $1,500,000. The number of shares that would be required to redeem the Calma NCI at December 31, 2021 is approximately 1,094,891. |
December 31, 2021 |
December 31, 2020 | |||||||
Interest allocable to Class A restricted voting shares |
$ |
— |
$ | 2,350,312 | ||||
Issuance costs |
— |
20,125,000 | ||||||
$ |
— |
$ | 22,475,312 | |||||
(i) | $25,000,000 on the effective date and; |
(ii) | $1,875,000 payable quarterly over the second year and third year terms. |
(i) | $2,000,000 within 30 days (Year 1) |
(ii) | $3,000,000 – Year 2 |
(iii) | $4,000,000 – Year 3 |
(iv) | $5,000,000 – Year 4 |
(v) | $6,000,000 – Year 5 |
(vi) | $6,500,000 – Year 6 |
a) |
Authorized |
a) |
Common shares issued |
Number of common shares |
||||
Balance, December 31, 2020 |
— |
|||
|
|
|||
(i) Conversion of Class B shares |
14,655,547 |
|||
(ii) Shares issued in a private placement |
6,313,500 |
|||
(iii) Conversion of Class A restricted voting shares |
31,407,336 |
|||
(iv) Shares issued to extinguish liabilities in the Qualifying Transaction |
336,856 |
|||
(v) Shares issued for the Qualifying Transaction |
42,891,175 |
|||
(vi) Contingent shares issued in the Qualifying Transaction |
25,000 |
|||
(vii) Share repurchases under repurchase agreements |
(1,725,000 |
) | ||
(viii) Share repurchases under normal course issuer bids |
(157,600 |
) | ||
(ix) Shares issued for contingent consideration |
24,584 |
|||
(x) Shares issued for acquisition of Calma |
458,898 |
|||
Shares issued for Marketing Service Agreement (Note 19) |
2,376,425 |
|||
Shares issued for vested RSUs (Note 20) |
455,058 |
|||
Shares issued for options exercised (Note 20) |
3,313 |
|||
|
|
|||
Balance, December 31, 2021 |
97,065,092 |
|||
|
|
(i) | Class B shares were converted into 14,655,547 common shares upon the closing of the Qualifying Transaction. |
(ii) | On January 15, 2021, the Company closed a private placement of 6,313,500 shares for subscription receipts and Class A restricted voting shares for consideration of $63,135,000 (Note 18). The subscription receipts and Class A restricted voting shares converted to common shares upon the closing of the Qualifying Transaction. |
(iii) | Upon the closing of the Qualifying Transaction, 31,407,336 Class A restricted voting shares were converted into common shares of the Company. The remaining 26,092,664 Class A restricted voting shares were redeemed for cash of $264,318,686. |
(iv) | The Company issued 336,856 common shares to settle a liability on behalf of SISU as part of the Qualifying Transaction. |
(v) | On January 15, 2021, the Company acquired Caliva and OGE, LCV and SISU as part of the Qualifying Transaction (Note 3). During the year ended December 31, 2021, the Company issued 42,891,175 common shares related to this transaction. |
(vi) |
During the year ended December 31, 2021, the Company settled a portion of the contingent shares to be issued as part of the Qualifying Transaction and issued 25,000 common shares . |
(v i i) |
During the year ended December 31, 2021, the Company repurchased 1,725,000 common shares under the shares repurchase agreements (Note 17). |
(v i ii) |
During the year ended December 31, 2021, the Neo Exchange Inc. accepted the Company’s notice of intention to commence Normal Course Issuer Bids (“NCIBs”) for the Company’s common shares and warrants. Pursuant to the NCIBs, the Company may repurchase on the open market (or as otherwise permitted), up to 4,912,255 common shares and 1,791,875 warrants, representing approximately 5% of the issued and outstanding of each of the common shares and the warrants subject to the normal terms and limitations of such bids and an aggregate cap of $25,000,000. Any common shares or warrants purchased under the NCIB will be cancelled. The NCIBs were effective on August 18, 2021 and end on the earlier of (i) August 17, 2022, (ii) $25,000,000 of purchases under the Bids, and (iii) the completion of purchases under the applicable Bid. As at December 31, 2021, the Company repurchased 157,600 common shares under this program for $603,165. |
(i x ) |
During the year ended December 31, 2021, the Company issued 24,584 common shares related to contingent consideration in the acquisition of LCV. The common shares were issued as the related contingency was resolved. |
( x |
On October 1, 2021, the Company acquired Calma (Note 11) and issued 458,898 common shares . |
a) |
Authorized |
b) |
Class B shares issued |
Number of Class B shares |
||||
Balance, December 31, 2020 |
15,218,750 |
|||
Conversion of Class B shares |
(14,655,547 |
) | ||
Founders’ shares forfeited |
(563,203 |
) | ||
Balance, December 31, 2021 |
— |
|||
Number of Warrants |
Weighted Average Exercise Price |
|||||||
Balance, December 31, 2019 |
35,837,500 |
$ | 11.50 | |||||
Granted |
— |
— |
||||||
Exercised |
— |
— |
||||||
Expired |
— | — | ||||||
Balance, December 31, 2020 and December 31, 2021 |
35,837,500 |
$ |
11.50 |
|||||
December 31, 2021 |
||||||||||||||||
Number of options |
Weighted average exercise price $ |
Weighted average remaining contractual term |
Aggregate intrinsic value |
|||||||||||||
Outstanding, beginning of period |
— | — | ||||||||||||||
Replacement options issued (i) |
1,113,006 | 7.76 | ||||||||||||||
Granted during the period |
— | — | ||||||||||||||
Exercised |
(9,477 | ) | 6.56 | |||||||||||||
Expired |
(96,100 | ) | 9.07 | |||||||||||||
Forfeited |
(250,726 | ) | 7.36 | |||||||||||||
Outstanding, end of period |
756,703 |
7.85 |
8.14 years |
$ |
0.00 |
|||||||||||
Vested and expected to vest in the future |
715,088 |
7.86 |
8.02 years |
$ |
0.25 |
|||||||||||
Exercisable |
476,191 |
7.87 |
7.72 years |
$ |
0.25 |
|||||||||||
Fair value |
||||
Allocated to pre-acquisition services (i) |
$ | 3,847,633 | ||
Allocated to post-combination services |
5,116,866 | |||
Total fair value of Replacement Options |
$ |
8,964,499 |
||
(i) | The portion allocated to pre-acquisition services relates to options that were and were not yet legally vested. The Company has applied a forfeiture rate to the options that have not legally vested to determine the amount to include in consideration. As a result, of the above amount, $3,489,501 has been included in consideration (Note 3). |
December 31, 2021 |
||||||||
Number of RSUs |
Weighted average grant date fair value |
|||||||
Non-vested, beginning of period |
— | — | ||||||
Granted |
2,253,696 | 1.99 | ||||||
Modified |
(1,708,696 | ) | 1.99 | |||||
Vested |
(288,150 | ) | — | |||||
Forfeited |
(256,850 | ) | 1.95 | |||||
Non-vested, end of period |
— | — | ||||||
December 31, 2021 |
||||||||
Number of RSUs |
Weighted average grant date fair value |
|||||||
Outstanding, beginning of period |
— | — | ||||||
Granted |
2,852,392 | 8.01 | ||||||
Modified |
1,708,696 | 1.99 | ||||||
Vested |
(717,486 | ) | 10.23 | |||||
Forfeited |
(533,582 | ) | — | |||||
Outstanding, end of period |
3,310,020 | 7.21 | ||||||
Number of shares |
Fair value on January 15, 2021 |
|||||||
Tranche 1 |
215,608 | $ | 2,597,618 | |||||
Tranche 2 |
215,608 | 2,314,652 | ||||||
Tranche 3 |
215,608 | 2,066,609 | ||||||
646,824 |
$ |
6,978,879 |
||||||
Number of Rights |
||||
Outstanding, beginning of period |
— | |||
Rights awarded |
646,824 | |||
Forfeited |
(283,974 | ) | ||
Outstanding, end of period |
362,850 |
|||
Replacement Options |
RSUs equity-settled | |||
Dividend yield |
— | — | ||
Expected volatility |
72% | — | ||
Risk-free interest rate |
0.17% - 0.71% |
— | ||
Share price |
$12.66 | — | ||
Grant date fair value |
$7.75 - $9.54 |
$3.35 – $12.66 | ||
Fair value on December 31, 2021 |
N/A | N/A |
December 31, 2021 |
December 31, 2020 |
|||||||
Replacement options |
$ |
1,920,392 |
$ |
— |
||||
Equity-settled RSUs |
8,271,869 |
— |
||||||
Cash-settled RSUs |
5,134,262 |
— |
||||||
Rights to contingent consideration |
5,129,774 |
— |
||||||
$ |
20,456,297 |
$ |
— |
|||||
December 31, 2021 |
December 31, 2020 |
|||||||
Loss available to common shareholders |
$ |
(587,060,124 |
) | $ | (6,463,606 | ) | ||
Adjustments to mezzanine equity |
— |
(22,475,312 | ) | |||||
Loss available to common shareholders adjusted for the effect of dilution |
$ |
(587,060,124 |
) | $ | (28,938,918 | ) | ||
Weighted average number of shares, basic and diluted |
95,006,080 |
15,218,750 | ||||||
Basic and diluted loss per share |
$ |
(6.18 |
) | $ | (1.90 | ) |
December 31, 2021 |
December 31, 2020 |
|||||||
Domestic - Canada |
$ |
165,628,760 |
$ | (6,463,606 | ) | |||
Foreign – outside of Canada |
(755,033,646 |
) |
— | |||||
$ |
(589,404,886 |
) |
$ |
(6,463,606 |
) | |||
December 31, 2021 |
December 31, 2020 |
|||||||
Current tax expense |
||||||||
Domestic – Canada |
$ | — | $ | — | ||||
Foreign – outside of Canada |
3,217,857 |
— | ||||||
3,217,857 |
— |
|||||||
Deferred tax recovery |
||||||||
Domestic – Canada |
— |
— | ||||||
Foreign – outside of Canada |
(5,590,409 |
) |
— | |||||
(5,590,409 |
) |
— | ||||||
Income tax recovery |
$ |
(2,372,552 |
) | $ | — | |||
December 31, 2021 |
December 31, 2020 |
|||||||
Loss before tax |
$ |
(589,404,886 |
) |
$ | (6,463,606 | ) | ||
Statutory income tax rate |
21 |
% |
27 | % | ||||
Income tax recovery based on statutory rate |
(123,775,026 |
) |
(1,745,174 | ) | ||||
Increase (decrease) resulting from: |
||||||||
§280E permanent adjustment |
22,558,050 |
— | ||||||
Impairment |
182,760,437 |
— | ||||||
Share -based compensation expense |
4,128,200 |
— | ||||||
Fair value change of contingent consideration |
(62,150,629 |
) |
— | |||||
Non-taxable items |
(1,286,101 |
) |
(634,584 | ) | ||||
Change in valuation allowance |
31,551,712 | 7,418,633 | ||||||
Other |
(647,879 | ) |
— | |||||
Share issuance costs recognized in equity |
— |
(5,433,750 | ) | |||||
Effect of state income taxes |
(65,515,675 |
) |
||||||
Tax rate differences and tax rate changes |
10,004,359 | 394,875 | ||||||
Income tax expense |
$ |
(2,372,552 |
) |
$ | — | |||
December 31, 2021 |
December 31, 2020 |
|||||||
Deferred tax assets |
||||||||
Loss carryforwards |
$ |
35,984,802 |
$ | 3,470,820 | ||||
Tangible assets |
1,148,865 |
— | ||||||
Intangible assets |
5,883,006 |
— |
||||||
Financing costs |
5,194,236 |
7,440,240 | ||||||
Marketing prepaid |
4,500,000 |
— | ||||||
Cash settled share-based payments |
1,395,000 |
— | ||||||
Other |
3,176,964 |
— | ||||||
Deferred tax assets |
57,282,873 |
10,911,060 | ||||||
Valuation allowance |
(42,459,208 |
) |
(10,911,060 | ) | ||||
Net deferred tax asset |
14,823,665 |
— | ||||||
Deferred tax liabilities |
||||||||
Intangible assets |
(58,294,219 |
) |
— | |||||
Other |
(377,312 |
) |
— | |||||
Deferred tax liabilities |
(58,671,531 |
) |
— | |||||
Deferred tax assets |
14,823,665 |
— | ||||||
Net deferred tax liability |
$ |
(43,847,866 |
) |
$ | — | |||
Federal |
State and Local |
Total |
||||||||||
2034 |
$ | — | $ | 48,671 | $ |
48,671 |
||||||
2035 |
— | 3,382,027 | 3,382,027 |
|||||||||
2036 |
— | 8,787,634 | 8,787,634 |
|||||||||
2037 |
— | 12,061,282 | 12,061,282 |
|||||||||
2038 |
— | 31,194,997 | 31,194,997 |
|||||||||
2039 |
— | 64,493,970 | 64,493,970 |
|||||||||
2040 |
— | 54,470,985 | 54,470,985 |
|||||||||
2041 |
— | 74,359,055 | 74,359,055 |
|||||||||
Indefinite |
9,534,555 | — | 9,534,555 |
|||||||||
$ |
9,534,555 |
$ |
248,798,621 |
$ |
258,333,176 |
|||||||
December 31, 2021 |
December 31, 2020 |
|||||||
General and administrative |
$ |
47,289,538 |
$ |
8,813,918 |
||||
Allowance for accounts receivable and notes receivable |
4,677,134 |
— |
||||||
Sales and marketing |
42,572,823 |
— | ||||||
Salaries and benefits |
36,864,880 |
— | ||||||
Share-based compensation (Note 22) |
20,456,297 |
— | ||||||
Lease expense |
4,956,969 |
— | ||||||
Depreciation of property and equipment and amortization of right-of-use assets |
3,890,425 |
— | ||||||
Amortization of intangible assets (Note 10) |
23,725,337 |
— | ||||||
$ |
184,433,403 |
$ | 8,813,918 | |||||
December 31, 2021 |
December 31, 2020 |
|||||||
Other assets |
$ |
385,812 |
$ | — | ||||
Non-THC business (i) |
2,070,689 |
— | ||||||
Sale of licenses (ii) |
(8,516 |
) |
— | |||||
$ |
2,447,985 |
$ | — | |||||
(i) | The Company became committed to a plan to sell its non-THC business in February 2021, which was acquired as part of the Caliva and OGE and LCV acquisitions (Note 3). As discussed in Note 16, the non-THC assets were tested for impairment and an impairment loss of $5,555,437 of goodwill was recognized and the remaining net assets were classified as held for sale. Subsequently, the Company disposed of these net assets for proceeds of $7,363,733, which comprised: (1) $4,318,537 of cash, (2) $885,722 of a promissory note (Note 7) and (3) $2,159,514 worth of common shares of Arcadia Wellness LLC (Note 8). |
(ii) | During the year ended December 31, 2021, the Company sold 100% of the share s |
December 31, 2021 |
December 31, 2020 |
|||||||
Lease liability (Note 13) |
$ |
4,515,112 |
$ | — | ||||
Other |
668,705 |
— | ||||||
$ |
5,183,817 |
$ | — | |||||
Change in working capital |
December 31, 2021 |
December 31, 2020 |
||||||
Accounts receivable |
$ |
(2,601,713 |
) |
$ | — | |||
Income tax receivables |
(1,322,340 |
) |
— |
|||||
Inventory |
(830,862 |
) |
— | |||||
Prepaid expenses |
(1,401,841 |
) |
— | |||||
Security deposits |
(36,336 |
) |
— | |||||
Prepaid expenses and other assets |
(675,635 |
) |
179,701 | |||||
Notes and other receivables |
(1,200,000 |
) |
581,400 | |||||
Cash settled share-based payments |
(1,682,898 |
) |
— | |||||
Accounts payable and accrued liabilities |
(36,761,461 |
) |
8,052,817 | |||||
|
|
|
|
|||||
$ |
(46,513,086 |
) |
$ | 8,813,918 | ||||
|
|
|
|
|||||
Cash paid |
||||||||
Income taxes |
$ |
4,753,710 |
$ | — |
December 31, 2021 |
December 31, 2020 |
|||||||
|
|
|
|
|||||
Lease payments – interest and principal (i) |
$ |
4,863,938 |
$ | — | ||||
Administrative fees and other costs (ii) |
5,000 |
351,449 | ||||||
|
|
|
|
|||||
$ |
4,868,938 |
$ | 351,449 | |||||
|
|
|
|
(i) | A director of the Company is a close family member to an owner of R&C Brown Associates, LP (“R&C”). The Company has 2 operating leases and 1 finance lease with R&C. Included in lease liabilities and right-o as at December 31, 2021 is f-use assets $41,053,363 (December 31, 2020 - $nil) and $28,035,112 (December 31, 2020 - $nil), respectively, with respect to leases with R&C. |
(ii) | Prior to the closing of the Qualifying Transaction, pursuant to an administrative services agreement between the Company and its Sponsor, dated July 16, 2019 (the “Administrative Services Agreement”), the Company provided a payment of $10,000 per month to the Sponsor for the utilization of office space, utilities and administrative support. The Company further reimbursed the Sponsor for $231,449 for any out-of-pocket |
(i) | R&C subscribed for 395,000 shares of the private placement that closed on January 15, 2021. |
(ii) | A founder and director of the Company had a 16.34% interest in LCV immediately prior to the Qualifying Transaction. The founder participated in the Qualifying Transaction, under the same terms and conditions as the other participants. |
(iii) |
The counterparty to the Marketing Agreement described in Note 19 became a related party in May 2021, when its Chief Executive Officer joined the Company’s Board of Directors. The Company expensed $3,284,018 related to this agreement since the counterparty became a related party. |
December 31, 2021 |
December 31, 2020 |
|||||||
Salaries and benefits |
$ |
3,197,006 |
$ | — | ||||
Share -based compensation |
10,793,993 |
— | ||||||
|
|
|
|
|||||
$ |
13,990,999 |
$ | — | |||||
|
|
|
|
a) |
California operating licenses |
b) |
Other legal matters |
c) |
Social equity fund |
Contingent consideration |
||||||||||||
Trading price consideration (i) |
Other (ii) |
Total |
||||||||||
Balance, January 1, 2021 |
$ | — | $ | — | $ |
— |
||||||
Additions (Note 3) |
232,719,246 | — | 232,719,246 |
|||||||||
Change in fair value |
(232,144,559 | ) | 2,325,489 | (229,819,070 |
) | |||||||
Transferred to equity |
— | (1,957,045 | ) | (1,957,045 |
) | |||||||
|
|
|
|
|
|
|||||||
Balance, December 31 2021 |
$ |
574,687 |
$ |
368,444 |
$ |
943,131 |
||||||
|
|
|
|
|
|
Key Inputs |
December 31, 2021 |
January 15, 2021 |
||||||
Key unobservable inputs |
||||||||
Expected volatility |
65 | % | 66 | % | ||||
Key observable inputs |
||||||||
Share price |
$ | 1.39 | $ | 12.66 | ||||
Risk-free interest rate |
0.79 | % | 0.20 | % | ||||
Dividend yield |
0 | % | 0 | % | ||||
Number of s hares |
21,850,404 | 21,566,431 |
Change in volatility |
December 31, 2021 |
January 15, 2021 |
||||||
+15% |
$ |
1,597,743 |
$ |
11,420,904 |
||||
-15% |
$ | (528,968 | ) |
$ | (17,250,641 | ) |
Gross |
Allowance |
Net |
||||||||||
Cash |
$ |
165,310,609 |
$ |
— |
$ |
165,310,609 |
||||||
Restricted cash and restricted cash equivalents |
9,581,689 |
— |
9,581,689 |
|||||||||
Accounts receivable (i) |
6,721,754 |
(2,016,191 |
) |
4,705,563 |
||||||||
Security deposits |
1,119,754 |
— |
1,119,754 |
|||||||||
Notes and other receivables (ii) |
7,393,560 |
(2,660,943 |
) |
4,732,617 |
||||||||
|
|
|
|
|
|
|||||||
$ |
190,127,366 |
$ |
(4,677,134 |
) |
$ |
185,450,232 |
||||||
|
|
|
|
|
|
December 31, 2021 |
||||
0-30 days |
$ |
4,723,810 |
||
31-60 days |
278,958 |
|||
61-90 days |
242,467 |
|||
91-120 days |
256,424 |
|||
Over 120 days |
|
|
1,220,095 |
|
|
|
|||
Gross receivables |
6,721,754 |
|||
Less allowance for doubtful accounts |
(2,016,191 |
) | ||
|
|
|||
$ |
4,705,563 |
|||
|
|
Carrying amount |
Fair value |
Level 1 |
Level 3 |
Total losses (gains) |
||||||||||||||||
Equity securities |
$ | 860,496 | $ | 860,496 | $ | 860,496 | $ | — | $ | 1,299,018 | ||||||||||
Debt securities |
1,048,028 | 1,048,028 | — | 1,048,028 | (48,028 | ) | ||||||||||||||
Total investments at fair value through profit or loss (Note 8) |
$ | 1,908,524 | $ | 1,908,524 | $ | 860,496 | $ | 1,048,028 | $ | 1,250,990 | ||||||||||
Contingent consideration – trading price consideration |
$ | 574,687 | $ | 574,687 | $ | — | $ | 574,687 | $ | (232,144,559 | ) | |||||||||
Contingent consideration - other |
368,444 | 368,444 | 368,444 | — | 2,325,489 | |||||||||||||||
Total contingent consideration (Note 32) |
$ | 943,131 | $ | 943,131 | $ | 368,444 | $ | 574,687 | $ | (229,819,070 | ) |
As at December 31, 2021 |
As at September 30, 2021 |
|||||||||||
Carrying amount |
Fair value |
Level 3 |
||||||||||
Licenses |
$ | 15,835,213 | $ | 17,433,794 | $ | 17,433,794 | ||||||
Cultivation network |
$ | 957,407 |
$ | 997,207 | $ | 997,207 |
December 31, 2021 |
||||
Assets |
||||
Current assets |
||||
Cash |
$ |
1,754,929 |
||
Restricted cash |
6,443,076 |
|||
Accounts receivable, net |
91,004 |
|||
Income tax receivable |
162,073 |
|||
Inventory |
1,199,662 |
|||
Prepaid expenses |
421,117 |
|||
Indemnification asset |
980,000 |
|||
Total current assets |
11,051,861 |
|||
Property and equipment, net |
5,110,894 |
|||
Goodwill and intangible assets |
61,724,905 |
|||
Right-of-use assets - operating |
12,199,466 |
|||
Total assets |
$ |
90,087,126 |
||
Liabilities |
||||
Current liabilities |
||||
Accounts payable and accrued liabilities |
$ |
6,724,680 |
||
Consideration payable – current portion |
1,331,724 |
|||
Operating lease liability – current portion |
935,346 |
|||
Total current liabilities |
8,991,750 |
|||
Operating lease liabilities |
11,681,587 |
|||
Deferred tax liabilities |
7,563,419 |
|||
Consideration payable |
1,827,515 |
|||
Total liabilities |
$ |
30,064,271 |
||
Exhibit 4.3
DESCRIPTION OF REGISTRANTS SECURITIES,
The following description of the securities of TPCO Holding Corp. (the Company, we, us, and our) is a summary and is not complete, may not contain all the information you should consider before investing in our securities and is qualified in its entirety by reference to our Notice of Articles and Articles (collectively, as amended, the Articles). The terms of these securities may also be affected by the Business Corporations Act (British Columbia) (the Act). All references to the Company, we, us, and our refer solely to TPCO Holding Corp. and do not include any subsidiary or affiliate of TPCO Holding Corp.
Capital Stock
Authorized Capital Stock
The Company is authorized to issue an unlimited number of common shares, no par value (the Common Shares). The Company also has an authorized class of proportionate voting shares (the Proportionate Voting Shares). On November 24, 2020, the Company announced it had entered into definitive transaction agreements to acquire all of the equity of each of CMG Partners, Inc. (Caliva) and Left Coast Ventures, Inc. (LCV), constituting the Companys qualifying transaction (the Qualifying Transaction). Concurrently with closing of the Qualifying Transaction, the Company exercised its right under the articles to require that all Proportionate Voting Shares be automatically converted into Common Shares on the basis of one hundred (100) Common Shares for one (1) Proportionate Voting Share. As a result of exercising this mandatory conversion right, the Company is no longer entitled to issue any further Proportionate Voting Shares.
As of December 31, 2021, the Company had 97,065,092 issued and outstanding Common Shares.
Voting Rights
All holders of Common Shares are entitled to receive notice of any meeting of shareholders of the Company, and to attend, vote and speak at such meetings, except those meetings at which only holders of a specific class of shares are entitled to vote separately as a class under the BCBCA. A quorum for the transaction of business at a meeting of shareholders is present if shareholders who, together, hold not fewer than 25% of the votes attaching to the outstanding voting shares entitled to vote at the meeting are present in person or represented by proxy. On all matters upon which holders of Common Shares are entitled to vote, each Common Share is entitled to one vote per Common Share. Unless a different majority is required by law or the Articles, resolutions to be approved by holders of Common Shares require approval by a simple majority of the total number of votes of all Common Shares cast at a meeting of shareholders at which a quorum is present.
Dividend Rights
Holders of Common Shares are entitled to receive dividends out of the assets available for the payment or distribution of dividends at such times and in such amount and form as the board of directors of the company (the Board) may from time to time determine.
Liquidation Rights
In the event of the liquidation, dissolution or winding-up of the Company or any other distribution of its assets among its shareholders for the purpose of winding-up its affairs, whether voluntarily or involuntarily, the holders of Common Shares will be entitled to receive all of the Companys assets remaining after payment of all debts and other liabilities on a pro rata basis.
Pre-emptive and Redemption Rights
Holders of Common Shares do not have any pre-emptive or redemption rights.
Compliance Provisions
The Articles facilitate compliance with applicable regulatory and/or licensing regulations. In particular, the Articles contain certain provisions (the Compliance Provisions), including a combination of certain remedies such as an automatic suspension of voting and/or dividend rights, a discretionary right to force a share transfer to a third party and/or a discretionary redemption right in favor of the Company, in each case to seek to ensure that the Company and its subsidiaries are able to comply with applicable regulatory and licensing regulations. The purpose of the Compliance Provisions is to provide the Company with a means of protecting itself from having a shareholder or a group of shareholders acting jointly or in concert, with an ownership interest of, whether of record or beneficially (or having the power to exercise control or direction over) (Owning or Controlling), five percent (5%) or more of the issued and outstanding shares of the Company, or such other number as is determined by the Board from time to time, and: (i) who a governmental authority granting licenses to, or otherwise governing the operations of, the Company or its subsidiaries has determined to be unsuitable to own Common Shares; (ii) whose ownership of Common Shares may reasonably result in the loss, suspension or revocation (or similar action) with respect to any licenses or permits relating to the Company or its subsidiaries conduct of business (being the conduct of any activities relating to the cultivation, manufacturing and dispensing of cannabis and cannabis-derived products in the United States, which include the owning and operating of cannabis licenses) or in the Company being unable to obtain any new licenses or permits in the normal course, all as determined by the Board; or (iii) who have not been determined by the applicable regulatory authority to be an acceptable person or otherwise have not received the requisite consent of such regulatory authority to own the Common Shares within a reasonable time period acceptable to the Board or prior to acquiring any Common Shares (in each case, an Unsuitable Person). The ownership restrictions in the Articles are also subject to an exemption for applicable depositaries and clearing houses as well as underwriters (as defined in the Securities Act (Ontario)) in the course of a distribution of securities of the Company.
Notwithstanding the foregoing, the Compliance Provisions provide that any shareholder (or group of shareholders acting jointly or in concert) proposing to Own or Control five percent (5%) or more of the issued and outstanding shares of the Company (or such other number as is determined by the Board from time to time) will be required to provide not less than 30 days advance written notice to the Company by mail sent to the Companys registered office to the attention of the Corporate Secretary and to obtain all necessary regulatory approvals. Upon any such shareholder(s) Owning or Controlling five percent (5%) or more of the issued and outstanding shares of the Company (or such other number as is determined by the Board from time to time), and having not received the requisite approval of any applicable regulatory authority to own the Common Shares the Compliance Provisions provide: (i) that such shareholder(s) may, in the discretion of the Board, be prohibited from exercising any voting rights and/or receiving any dividends from the Company, unless and until all requisite regulatory approvals are obtained; and (ii) the Company with a right, but not the obligation, at its option, upon notice to the Unsuitable Person, to: (A) redeem any or all Common Shares directly or indirectly held by an Unsuitable Person; and/or (B) forcibly transfer any or all Common Shares directly or indirectly held directly or indirectly by an Unsuitable Person to a third party. Such rights are required in order for the Company to comply with regulations in various jurisdictions where the Company or its subsidiaries may conduct business.
Upon receipt by the holder of a notice to redeem or to transfer any or all of its Common Shares the holder will be entitled to receive, as consideration therefor, no less than 95% of the lesser of: (i) the closing price of the Common Shares listed on the Neo Exchange, Inc. (the Exchange) (or the then principal exchange on which the Companys securities are quoted for trading) on the trading day immediately prior to the closing of the redemption or transfer (or the average of the last bid and last asking prices if there was no trading on the specified date); and (ii) the five-day volume weighted average trading price (VWAP) of the Common Shares on the Exchange (or the then principal exchange on which the Companys securities are quoted for trading) for the five trading days immediately prior to the closing of the redemption or transfer (or the average of the last bid and last asking prices if there was no trading on the specified dates).
Further, a holder of the Common Shares is be prohibited from acquiring five percent (5%) or more of the issued and outstanding shares of the Company, directly or indirectly, in one or more transactions, without providing 30 days advance written notice to the Company by mail sent to the Companys registered office to the attention of the Corporate Secretary. The foregoing restriction do not apply to the ownership, acquisition or disposition of Common Shares as a result of: (i) transfer of Common Shares occurring by operation of law including, inter alia, the transfer
of Common Shares to a trustee in bankruptcy, (ii) an acquisition or proposed acquisition by one or more underwriters who hold Common Shares for the purposes of distribution to the public or for the benefit of a third party provided that such third party is in compliance with the foregoing restriction, or (iii) conversion, exchange or exercise of securities issued by the Company or a subsidiary into or for Common Shares in accordance with their respective terms. If the Board reasonably believes that any such holder of the Common Shares may have failed to comply with the foregoing restrictions, the Company may apply to the Supreme Court of British Columbia, or any other court of competent jurisdiction, for an order directing that such shareholder disclose the number of Common Shares directly or indirectly held.
Notwithstanding the Compliance Provisions, the Company may not be able to exercise such rights in full or at all, including its redemption rights. Under the BCBCA, a corporation may not make any payment to redeem shares if there are reasonable grounds for believing that the company is unable to pay its liabilities as they become due in the ordinary course of its business or if making the payment of the redemption price or providing the consideration would cause the company to be unable to pay its liabilities as they become due in the ordinary course of its business. Furthermore, the Company may become subject to contractual restrictions on its ability to redeem its Common Shares by, for example, entering into a secured credit facility subject to such restrictions. In the event that restrictions prohibit the Company from exercising its redemption rights in part or in full, the Company will not be able to exercise its redemption rights absent a waiver of such restrictions, which the Company may not be able to obtain on acceptable terms or at all.
Advance Notice Requirements for Director Nominations
The Company has included certain advance notice provisions with respect to the election of its directors in the Articles (the Advance Notice Provisions). The Advance Notice Provisions are intended to: (i) facilitate orderly and efficient annual general meetings or, where the need arises, special meetings; (ii) ensure that all shareholders receive adequate notice of director nominations to the Board and sufficient information with respect to all nominees; and (iii) allow shareholders to register an informed vote. Only persons who are nominated by shareholders in accordance with the Advance Notice Provisions will be eligible for election as directors at any annual meeting of shareholders, or at any special meeting of shareholders if one of the purposes for which the special meeting was called was the election of directors. Under the Advance Notice Provisions, a shareholder wishing to nominate a director would be required to provide the Company notice, in the prescribed form, within the prescribed time periods. These time periods include, (i) in the case of an annual meeting of shareholders (including annual and special meetings), not fewer than 30 days prior to the date of the annual meeting of shareholders; provided, that if the first public announcement of the date (the Notice Date) of the annual meeting of shareholders is less than 50 days before the meeting date, not later than the close of business on the 15th day following the Notice Date; and (ii) in the case of a special meeting (which is not also an annual meeting) of shareholders called for any purpose which includes electing directors, not later than the close of business on the 15th day following the Notice Date, provided that, in either instance, if notice-and-access (as defined in National Instrument 54-101 Communication with Beneficial Owners of Securities of a Reporting Issuer) is used for delivery of proxy related materials in respect of a meeting described above, and the Notice Date in respect of the meeting is not fewer than 50 days prior to the date of the applicable meeting, the notice must be received not later than the close of business on the 40th day before the applicable meeting.
Forum Selection Provision
The Articles include, among other provisions, a provision providing for a forum for adjudication of certain disputes, whereby unless the Company approves or consents in writing to the selection of an alternative forum, the courts of the Province of British Columbia and appellate courts therefrom shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim for breach of a fiduciary duty owed by any director or officer of the Company to the Company, (iii) any action asserting a claim arising pursuant to any provision of the BCBCA or the Articles (as they may be amended from time to time), or (iv) any action asserting a claim otherwise related to the relationships among the Company, its affiliates and their respective shareholders, directors and/or officers, but does not include claims related to the business carried on by the Company or such affiliates. Any person or entity owning, purchasing or otherwise acquiring any interest, including without limitation any registered or beneficial ownership thereof, in the securities of the Company shall be deemed to have notice of and consented to the provisions of the Articles.
The Articles do not limit the ability of investors to bring direct actions outside of British Columbia, Canada, including those arising under the Securities Exchange Act if 1934, as amended (the Exchange Act) and the Securities Act of 1933, as amended (the Securities Act). Section 27 of the Exchange Act creates exclusive federal jurisdiction over actions brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder, and Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. Neither investor nor the Company and may waive compliance with the U.S. federal securities laws and the rules and regulations thereunder, and it is therefore uncertain whether the exclusive forum provision of the Articles would be enforced by a court as to derivative claims brought under the Exchange Act or the Securities Act.
Warrants
General
As of December 31, 2021, there were 35,837,500 share purchase warrants (Warrants) issued and outstanding. Each Warrant became exercisable for one Common Share at an exercise price of $11.50 per Common Share on March 21, 2021.
Expiration Date
The Warrants will expire at 5:00 p.m. Eastern Time (ET) on January 15, 2026 or may expire earlier upon the Companys winding-up or if the expiry date is accelerated.
Exercise and Acceleration of the Warrants
The Warrants are exercisable pursuant to the terms of the warrant agency agreement between the Company and Odyssey Trust Company, as warrant agent, dated July 16, 2019 (the Warrant Agreement). Tthe Company may accelerate the expiry date of the outstanding Warrants (excluding the warrants held by Subversive Capital Sponsor LLC (the Sponsor) but only to the extent still held by the Sponsor at the date of public announcement of such acceleration and not transferred prior to the accelerated expiry date, due to the anticipated knowledge by the Sponsor of material undisclosed information which could limit their dealings in such securities) by providing 30 days notice if, and only if, the closing price of the Common Shares equals or exceeds $18.00 per Common Share (as adjusted for stock splits or combinations, stock dividends, Extraordinary Dividends (as defined below), reorganizations and recapitalizations and the like) for any 20 trading days within a 30-trading day period. An Extraordinary Dividend means any dividend, together with all other dividends payable in the same calendar year by the Company, that has an aggregate absolute dollar value which is greater than $0.25 per Common Share, with the adjustment to the applicable price (as the context may require) being a reduction equal to the amount of the excess.
The right to exercise will be forfeited unless the Warrants are exercised prior to the date specified in the notice of acceleration of the expiry date. On and after the acceleration of the expiry date, a record holder of a Warrant will have no further rights.
Adjustments to Exercise Price
The exercise price and number of shares issuable on exercise of the Warrants may be adjusted in certain circumstances, including in the event of a stock dividend, Extraordinary Dividend, or our recapitalization, reorganization, merger or consolidation. The Warrants will not, however, be adjusted for issuances of shares at a price below their exercise price.
No Fractional Shares
Warrants may be exercised only for a whole number of shares. No fractional shares will be issued upon exercise of the Warrants. If, upon exercise of the Warrants, a holder would be entitled to receive a fractional interest in a share, it will, upon exercise, be rounded down to the nearest whole number of shares to be issued to the Warrant holder.
Applicability of U.S. Securities Laws to Exercise of Warrants
The exercise of the Warrants by any holder in the United States, or that is a U.S. person, may only be effected in compliance with an exemption from the registration requirements of the Securities Act and applicable State blue sky securities laws.
No Voting Rights
Warrant holders do not have the rights or privileges of holders of shares and any voting rights until they exercise their Warrants and receive corresponding Common Shares. After the issuance of corresponding Common Shares upon exercise of the Warrants, each holder will be entitled to one vote for each Common Share held of record on all matters to be voted on by shareholders. The warrant agent shall, on receipt of a written request of the Company or holders of not less than 25% of the aggregate number of Warrants then outstanding, convene a meeting of holders of Warrants upon at least 21 calendar days written notice to holders of Warrants. Every such meeting shall be held in Toronto, Ontario or at such other place as may be approved or determined by the warrant agent. A quorum at meetings of holders of Warrants shall be two persons present in person or represented by proxy holding or representing more than 20% of the aggregate number of Warrants then outstanding.
Amendments to Warrant Agreement
From time to time, the Company and the warrant agent, without the consent of the holders of Warrants, may amend or supplement the Warrant Agreement for certain purposes including curing defects or inconsistencies or making any change that does not adversely affect the rights of any holder of Warrants. Any amendment or supplement to the Warrant Agreement that adversely affects the interests of the holders of Warrants may only be made by an extraordinary resolution, which is defined in the Warrant Agreement as a resolution either (i) passed at a meeting of the holders of Warrants by the affirmative vote of holders of Warrants representing not less than two-thirds of the aggregate number of the then outstanding Warrants represented at the meeting and voted on such resolution, or (ii) adopted by an instrument in writing signed by the holders of Warrants representing not less than two-thirds of the aggregate number of the then outstanding Warrants.
Exhibit 21.1
SUBSIDIARIES OF THE REGISTRANT
The following is a list of subsidiaries of TPCO Holding Corp., omitting subsidiaries which, considered in the aggregate as a single subsidiary, would not constitute a significant subsidiary as of December 31, 2021:
Name of Subsidiary |
Jurisdiction of Incorporation or Organization | |
TPCO US Holding LLC |
Delaware | |
CMG Partners, Inc. |
Delaware | |
Left Coast Ventures, Inc. |
Delaware | |
NC3 Systems (d.b.a. Caliva) |
California | |
Caliva CAMISJ2, Inc. (d.b.a. Deli by Caliva San Jose, Calive) |
California | |
Fluid South, Inc. (d.b.a. Sol Distro, Caliva) |
California |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement No. 333-260978 on Form S-8 of TPCO Holding Corp. (the Company) of our report dated March 31, 2022, on the consolidated financial statements of the Company, which comprise the consolidated balance sheets as of December 31, 2021 and December 31, 2020, the related consolidated statements of operations and comprehensive loss, changes in shareholders (deficit) equity and cash flows for each of the years in the two-year period ended December 31, 2021, and the related notes, which report appears in the Companys Annual Report on Form 10-K (File No. 0-56348) filed with the Securities and Exchange Commission on March 31, 2022.
/s/ MNP LLP
Chartered Professional Accountants
Licensed Public Accountants
Toronto, Canada
March 31, 2022
Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Troy Datcher, certify that:
1. | I have reviewed this Annual Report on Form 10-K of TPCO Holding Corp.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrants other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) [language omitted in accordance with Exchange Act Rule 13a-14(a)] for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | [language omitted in accordance with Exchange Act Rule 13a-14(a)]; |
c. | Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and |
5. | The registrants other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions): |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. |
Date: March 31, 2022 | By: | /s/ Troy Datcher | ||
Troy Datcher | ||||
Chief Executive Officer (Principal Executive Officer) |
Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Mike Batesole, certify that:
1. | I have reviewed this Annual Report on Form 10-K of TPCO Holding Corp.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrants other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) [language omitted in accordance with Exchange Act Rule 13a-14(a)] for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | [language omitted in accordance with Exchange Act Rule 13a-14(a)]; |
c. | Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and |
5. | The registrants other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions): |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. |
Date: March 31, 2022 | By: | /s/ Mike Batesole | ||
Mike Batesole | ||||
Chief Financial Officer (Principal Financial Officer) |
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of TPCO Holding Corp. (the Company) on Form 10-K for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Troy Datcher, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
(2) | The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
March 31, 2022 | /s/ Troy Datcher | |||
Troy Datcher | ||||
Chief Executive Officer | ||||
(Principal Executive Officer) |
A signed original of this written statement required by Section 906 has been provided to TPCO Holding Corp. and will be retained by TPCO Holding Corp. and furnished to the Securities and Exchange Commission or its staff upon request.
Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of TPCO Holding Corp. (the Company) on Form 10-K for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Mike Batesole, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
(2) | The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
March 31, 2022 | /s/ Mike Batesole | |||
Mike Batesole | ||||
Chief Financial Officer | ||||
(Principal Financial Officer) |
A signed original of this written statement required by Section 906 has been provided to TPCO Holding Corp. and will be retained by TPCO Holding Corp. and furnished to the Securities and Exchange Commission or its staff upon request.